[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 122
1. Chang JE, Voorhees PM, Kolesar JM, Ahuja HG, Sanchez FA, Rodriguez GA, Kim K, Werndli J, Bailey HH, Kahl BS: Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study. Hematol Oncol; 2009 Mar;27(1):11-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study.
  • This multi-institution phase II study investigated a novel dosing schedule of As(2)O(3) and AA in patients with relapsed or refractory lymphoid malignancies.
  • The trial, which had been designed as a two-stage study, was closed after the first stage analysis due to lack of activity.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Vitamin C.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 John Wiley & Sons, Ltd.
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1341-8 [9801394.001]
  • [Cites] Leukemia. 1998 Sep;12(9):1383-91 [9737686.001]
  • [Cites] J Natl Cancer Inst. 1999 May 5;91(9):772-8 [10328107.001]
  • [Cites] Blood. 1999 Sep 15;94(6):2102-11 [10477740.001]
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2387-401 [15621751.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1687-92 [16130126.001]
  • [Cites] Leuk Lymphoma. 2006 Mar;47(3):521-9 [16396776.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2627-32 [16352810.001]
  • [Cites] Med Oncol. 2006;23(2):263-72 [16720927.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2465-71 [16651646.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2456-64 [16651647.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2624-9 [16688776.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1105-8 [16870552.001]
  • [Cites] Br J Haematol. 2006 Oct;135(2):174-83 [17010047.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3315-24 [10552940.001]
  • [Cites] Br J Cancer. 1999 Nov;81(5):796-9 [10555748.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Blood. 2000 Feb 1;95(3):1014-22 [10648417.001]
  • [Cites] Br J Haematol. 2001 Mar;112(3):783-6 [11260084.001]
  • [Cites] Oncologist. 2001;6 Suppl 2:17-21 [11331436.001]
  • [Cites] Oncologist. 2001;6 Suppl 2:22-8 [11331437.001]
  • [Cites] Blood. 2001 Aug 1;98(3):805-13 [11468182.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1835-7 [12200700.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3658-68 [12473574.001]
  • [Cites] Leukemia. 2003 Jan;17(1):271-2 [12529694.001]
  • [Cites] Hum Exp Toxicol. 2002 Dec;21(12):675-80 [12540038.001]
  • [Cites] Cancer. 2003 May 1;97(9):2218-24 [12712474.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1028-34 [12676792.001]
  • [Cites] J Nutr Biochem. 2003 Jul;14(7):416-20 [12915223.001]
  • [Cites] Br J Haematol. 2004 May;125(4):470-6 [15142117.001]
  • [Cites] Anal Biochem. 1969 Mar;27(3):502-22 [4388022.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):194-205 [8270977.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7 Suppl):1969s-1975s [8137322.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Blood. 1996 Aug 1;88(3):1052-61 [8704214.001]
  • [Cites] Blood. 1997 May 1;89(9):3345-53 [9129041.001]
  • [Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]
  • [Cites] Blood. 1997 Jul 15;90(2):562-70 [9226155.001]
  • [Cites] J Natl Cancer Inst. 1997 Dec 3;89(23):1789-96 [9392620.001]
  • [Cites] Br J Haematol. 1998 Sep;102(4):1055-60 [9734658.001]
  • [Cites] Blood. 1999 Jan 1;93(1):268-77 [9864170.001]
  • (PMID = 18668698.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K12 CA087718-09; United States / NCI NIH HHS / CA / CA087718-08; United States / NCI NIH HHS / CA / K12 CA087718-07; United States / NCI NIH HHS / CA / K12 CA087718; United States / NCI NIH HHS / CA / CA087718-09; United States / NCI NIH HHS / CA / CA087718-10; United States / NCI NIH HHS / CA / K12 CA087718-10; United States / NCI NIH HHS / CA / K12 CA087718-08
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; GAN16C9B8O / Glutathione; PQ6CK8PD0R / Ascorbic Acid; S7V92P67HO / arsenic trioxide
  • [Other-IDs] NLM/ NIHMS212975; NLM/ PMC2897137
  •  go-up   go-down


2. Aragon-Ching JB, Jain L, Gulley JL, Arlen PM, Wright JJ, Steinberg SM, Draper D, Venitz J, Jones E, Chen CC, Figg WD, Dahut WL: Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int; 2009 Jun;103(12):1636-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
  • OBJECTIVE: To determine if sorafenib is associated with an improved 4-month probability of progression-free survival, using radiographic and clinical criteria alone, in patients with metastatic castration-resistant prostate cancer.
  • PATIENTS AND METHODS: The study was an open-label, phase II, two-stage design, focusing on the results from the second stage, as criteria for progression were modified after completing the first stage.
  • RESULTS: Twenty-four patients were accrued in the second stage; the median (range) age was 66 (49-85) years, the on-study prostate-specific antigen level was 68.45 (5.8-995) ng/mL, the Gleason score 8 (6-9) and Eastern Cooperative Oncology Group status 1 (in 17 patients).
  • CONCLUSIONS: Sorafenib has moderate activity as a second-line treatment for metastatic castration-resistant prostate cancer.


3. Masson P, Alves AC, Ebbels TM, Nicholson JK, Want EJ: Optimization and evaluation of metabolite extraction protocols for untargeted metabolic profiling of liver samples by UPLC-MS. Anal Chem; 2010 Sep 15;82(18):7779-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These protocols, designed to extract both polar and nonpolar metabolites, were based on (i) a two stage extraction approach or (ii) a simultaneous extraction in a biphasic mixture, employing different volumes and combinations of extraction and resuspension solvents.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DICHLOROMETHANE .
  • Hazardous Substances Data Bank. Water .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20715759.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Solvents; 059QF0KO0R / Water; 588X2YUY0A / Methylene Chloride
  •  go-up   go-down


Advertisement
4. Beaty O 3rd, Berg S, Blaney S, Malogolowkin M, Krailo M, Knight R, Schaiquevich P, Stewart C, Chen Z, Nelson M, Voss S, Ivy SP, Adamson PC: A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer; 2010 Sep;55(3):440-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study.
  • A two-stage design, enrolling 10 + 10 subjects, was used for each disease stratum.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20658614.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10CA98413; United States / NCI NIH HHS / CA / U10CA98543; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA098543-08; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA098413-08
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin
  • [Other-IDs] NLM/ NIHMS218622; NLM/ PMC4665115
  •  go-up   go-down


5. Kato T, Takagi H, Mori Y, Sakamoto K, Yamada T, Umeda Y, Fukumoto Y, Hirose H: Simultaneous operation of ischemic heart disease, abdominal aortic aneurysm, and rectal cancer. Heart Vessels; 2005 Jul;20(4):167-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous operation of ischemic heart disease, abdominal aortic aneurysm, and rectal cancer.
  • A 68-year-old man with ischemic heart disease, abdominal aortic aneurysm, and rectal cancer was referred.
  • Barium enema revealed stenosis 4 cm in length 5 cm inward from the anal verge, and an endoscopic finding was ulcerated type tumor with a clear margin and circumferential stenosis.
  • Histological examination of a biopsy specimen revealed adenocarcinoma, and the clinical stage in the Japanese classification of colorectal carcinoma was II according to other examinations.
  • Simultaneous operations were scheduled because of the jeopardized collaterals of the coronary arteries, rapid expansion of the aneurysm, and subileus due to the cancer.
  • The patient is doing well 12 months after the operation, without myocardial ischemic symptoms or recurrence of the cancer.


6. Jones AE, Brown KC, Werner RE, Gotzkowsky K, Gaedigk A, Blake M, Hein DW, van der Horst C, Kashuba AD: Variability in drug metabolizing enzyme activity in HIV-infected patients. Eur J Clin Pharmacol; 2010 May;66(5):475-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: Infection with HIV or stage of HIV infection may alter Phase I and II drug metabolizing enzyme activity.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DEXTROMETHORPHAN .
  • Hazardous Substances Data Bank. CAFFEINE .
  • Hazardous Substances Data Bank. Midazolam .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacogenetics. 1999 Dec;9(6):715-23 [10634134.001]
  • [Cites] Clin Pharmacol Ther. 1994 Jun;55(6):649-60 [8004881.001]
  • [Cites] Pharmacogenetics. 2000 Apr;10(3):187-216 [10803676.001]
  • [Cites] Pharmacotherapy. 2000 Aug;20(8):898-907 [10939550.001]
  • [Cites] Eur J Clin Pharmacol. 2000 Jun;56(3):231-40 [10952478.001]
  • [Cites] Pharmacogenetics. 2000 Oct;10(7):577-81 [11037799.001]
  • [Cites] Anal Biochem. 2001 Jan 1;288(1):106-8 [11141315.001]
  • [Cites] Drug Metab Dispos. 2001 Mar;29(3):207-12 [11181485.001]
  • [Cites] Am J Gastroenterol. 2001 Apr;96(4):1194-9 [11316169.001]
  • [Cites] Clin Pharmacol Ther. 2002 Jul;72(1):76-89 [12152006.001]
  • [Cites] FASEB J. 2002 Nov;16(13):1799-801 [12354697.001]
  • [Cites] Crit Care Med. 2003 May;31(5):1338-46 [12771600.001]
  • [Cites] J Biomed Sci. 2003 Sep-Oct;10(5):552-64 [12928596.001]
  • [Cites] Drug Metab Dispos. 2004 Mar;32(3):359-63 [14977871.001]
  • [Cites] Mol Interv. 2003 Jun;3(4):194-204 [14993447.001]
  • [Cites] Clin Pharmacol Ther. 2004 Aug;76(2):128-38 [15289790.001]
  • [Cites] Clin Pharmacol Ther. 1976 Apr;19(4):459-67 [773582.001]
  • [Cites] Lancet. 1978 May 27;1(8074):1132-3 [77421.001]
  • [Cites] Clin Pharmacol Ther. 1985 Jun;37(6):701-4 [4006370.001]
  • [Cites] Cancer Res. 1988 Apr 15;48(8):2107-12 [2450644.001]
  • [Cites] Clin Pharmacol Ther. 1989 Oct;46(4):399-407 [2791443.001]
  • [Cites] Can J Physiol Pharmacol. 1990 Jun;68(6):777-81 [1695539.001]
  • [Cites] Can J Physiol Pharmacol. 1991 Jul;69(7):944-50 [1720069.001]
  • [Cites] Clin Pharmacol Ther. 1993 May;53(5):529-35 [8491064.001]
  • [Cites] Biochem Pharmacol. 1993 Dec 3;46(11):2114-7 [7505583.001]
  • [Cites] Life Sci. 1994;55(22):1701-9 [7968249.001]
  • [Cites] Antiviral Res. 1994 Jul;24(2-3):221-33 [7526793.001]
  • [Cites] Pharmacogenetics. 1994 Aug;4(4):171-84 [7987401.001]
  • [Cites] Br J Clin Pharmacol. 1994 Dec;38(6):581-2 [7888297.001]
  • [Cites] Hepatology. 1995 Oct;22(4 Pt 1):1143-53 [7557864.001]
  • [Cites] Microbiol Rev. 1995 Sep;59(3):481-505 [7565415.001]
  • [Cites] J Lab Clin Med. 1997 Jan;129(1):10-6 [9011585.001]
  • [Cites] Pharmacotherapy. 1997 Mar-Apr;17(2):205-23 [9085311.001]
  • [Cites] Clin Pharmacol Ther. 1997 Sep;62(3):261-71 [9333101.001]
  • [Cites] Drug Metab Rev. 1997 Nov;29(4):1129-88 [9421688.001]
  • [Cites] Clin Pharmacol Ther. 1998 May;63(5):540-51 [9630827.001]
  • [Cites] Ther Drug Monit. 1998 Aug;20(4):371-5 [9712458.001]
  • [Cites] Clin Pharmacol Ther. 1998 Sep;64(3):269-77 [9757150.001]
  • [Cites] Pharmacogenetics. 1998 Oct;8(5):403-10 [9825832.001]
  • [Cites] Pharmacogenetics. 1998 Dec;8(6):529-41 [9918137.001]
  • [Cites] Drug Metabol Drug Interact. 2004;20(4):247-61 [15663294.001]
  • [Cites] Drug Metab Dispos. 2005 May;33(5):603-13 [15673596.001]
  • [Cites] Pharmacogenomics J. 2005;5(3):173-82 [15768052.001]
  • [Cites] Drug Metab Dispos. 2005 Jul;33(7):884-7 [15833928.001]
  • [Cites] Curr Drug Targets Immune Endocr Metabol Disord. 2005 Dec;5(4):439-48 [16375696.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2006;46:123-49 [16402901.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Mar;26(3):475-80 [16385082.001]
  • [Cites] Oncogene. 2006 Mar 13;25(11):1649-58 [16550165.001]
  • [Cites] J Virol. 2006 Dec;80(23):11486-97 [17005663.001]
  • [Cites] Expert Rev Anti Infect Ther. 2006 Oct;4(5):767-80 [17140354.001]
  • [Cites] Clin Pharmacol Ther. 2007 Feb;81(2):298-304 [17259955.001]
  • [Cites] Clin Pharmacol Ther. 2008 Feb;83(2):234-42 [17971818.001]
  • [Cites] J Clin Pharmacol. 2008 Jun;48(6):662-70 [18378963.001]
  • [Cites] Child Adolesc Psychiatr Clin N Am. 2000 Jan;9(1):43-76 [10674190.001]
  • (PMID = 20084375.001).
  • [ISSN] 1432-1041
  • [Journal-full-title] European journal of clinical pharmacology
  • [ISO-abbreviation] Eur. J. Clin. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000046; United States / NCRR NIH HHS / RR / RR000046-421072; United States / NIAID NIH HHS / AI / AI054980-05; United States / NIAID NIH HHS / AI / AI54980; United States / NCRR NIH HHS / RR / M01 RR000046-421072; United States / NIAID NIH HHS / AI / K23 AI054980-05; United States / NCRR NIH HHS / RR / RR00046; United States / NIAID NIH HHS / AI / K23 AI054980
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 3G6A5W338E / Caffeine; 7355X3ROTS / Dextromethorphan; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.17.3.2 / Xanthine Oxidase; EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / NAT2 protein, human; R60L0SM5BC / Midazolam
  • [Other-IDs] NLM/ NIHMS190674; NLM/ PMC2855129
  •  go-up   go-down


7. Ferrigno R, Nakamura RA, Dos Santos Novaes PE, Pellizzon AC, Maia MA, Fogarolli RC, Salvajoli JV, Filho WJ, Lopes A: Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. Int J Radiat Oncol Biol Phys; 2005 Mar 15;61(4):1136-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness.
  • PURPOSE: This retrospective analysis reports the results on patients with anal canal carcinoma treated by combined radiotherapy and chemotherapy.
  • METHODS AND MATERIALS: Between March 1993 and December 2001, 43 patients with anal canal carcinoma were treated with radiochemotherapy at the Hospital do Cancer A.C. Camargo.
  • Stage distribution was as follows: I, 3 (7%); II, 23 (53.5%); IIIA, 8 (18.6%); and IIIB, 9 (21%).
  • Patient's age, tumor stage, overall treatment time, and RT dose at primary tumor were variables analyzed for survival and local control.
  • Overall survival according to clinical stage was as follows: I, 100%; II, 82%; IIIA, 73%; and IIIB, 18% (p = 0.0049).
  • CONCLUSIONS: This analysis suggests that the treatment scheme employed was effective for anal sphincter preservation and local control; however, the incidence of distant metastases was relatively high.
  • The clinical stage was the main prognostic factor for overall survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15752894.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Biondo S, Kreisler E, Millan M, Martí-Ragué J, Fraccalvieri D, Golda T, De Oca J, Osorio A, Fradera R, Salazar R, Rodriguez-Moranta F, Sanjuán X: [Long-term results of emergency surgery for colon cancer compared with elective surgery]. Cir Esp; 2007 Aug;82(2):89-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results of emergency surgery for colon cancer compared with elective surgery].
  • [Transliterated title] Resultados a largo plazo de la cirugía urgente y electiva del cáncer de colon. Estudio comparativo.
  • AIMS: The aim of the present study was to analyze the 5-year efficacy of curative oncological surgery for complicated colon cancer performed in an emergency setting in terms of tumor recurrence and survival compared with elective surgery of uncomplicated tumors.
  • PATIENTS AND METHOD: We performed a prospective observational cohort study in patients who underwent emergency surgery for complicated colon cancer (group 1) and patients who underwent elective surgery (group 2).
  • Exclusion criteria were tumors of less than 15 cm from the anal verge, palliative surgery, and distant metastases.
  • Significant differences were found in disease stage between the 2 groups (P = 0.003).
  • When patients were stratified by TNM stage, worse 5-year cancer-related and disease-free survival rates were observed in group 1 patients with stage II tumors.
  • No differences were found in cancer-related survival rates in stage III patients (P = 0.178).
  • There were no significant differences in overall survival, cancer-related survival or tumor recurrence rates when group 1 was compared with a subgroup of patients in group 2 with factors of poor prognosis.
  • CONCLUSIONS: Complicated colon cancer presents in more advanced stages and had a worse overall long-term prognosis than uncomplicated tumour.
  • These differences decrease when patients are subclassified by tumoral stage.
  • Overall survival and cancer-related survival rates similar to those of elective surgery can be achieved in emergency surgery when curative oncological resection is performed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17785142.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


9. de Graeff P, Crijns AP, Ten Hoor KA, Klip HG, Hollema H, Oien K, Bartlett JM, Wisman GB, de Bock GH, de Vries EG, de Jong S, van der Zee AG: The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer; 2008 Jul 22;99(2):341-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer.
  • Ovarian cancer is the most frequent cause of death from gynaecological cancer in the Western world.
  • Current prognostic factors do not allow reliable prediction of response to chemotherapy and survival for individual ovarian cancer patients.
  • Epidermal growth factor receptor (EGFR) and HER-2/neu are frequently expressed in ovarian cancer but their prognostic value remains unclear.
  • In this study, we investigated the expression and prognostic value of EGFR, EGFR variant III (EGFRvIII), HER-2/neu and important downstream signalling components in a large series of epithelial ovarian cancer patients.
  • Our results show that negative PTEN immunostaining was associated with stage I/II disease (P=0.006), non-serous tumour type (P=0.042) and in multivariate analysis with a longer progression-free survival (P=0.015).
  • Positive pAKT staining was associated with advanced-stage disease (P=0.006).


10. Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, Paty PB, Weiser MR, Neuman HB, Shia J, Schrag D, Temple LK: Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum; 2008 Feb;51(2):147-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous-cell carcinoma of the anal canal: predictors of treatment outcome.
  • PURPOSE: The incidence of anal canal squamous-cell carcinoma is increasing.
  • METHODS: Using one database, we identified 131 Stages I-III patients treated for primary anal canal squamous-cell carcinoma at our institution from December 1986 to August 2006, with minimum six-month follow-up.
  • RESULTS: Of 131 patients (median age, 58.3 years; median follow-up, 2.9 (range, 0.6-11.2) years), 66 percent were females, 43.5 percent were Stage II, and 11 (8 percent) were HIV-positive.
  • Almost all patients undergoing radiotherapy (96.7 percent, 118/122) also had chemotherapy: 118 (100 percent, Stages I-III) had concurrent chemotherapy: (98 (83.8 percent) mitomycin/5-fluorouracil, 12 (10.2 percent) cisplatin/5-fluorouracil, 8 (6.8 percent) 5-fluorouracil alone); 35 of 46 (76 percent) Stage III patients received induction chemotherapy (34 (97.1 percent) cisplatin/5-fluorouracil, 1 (2.8 percent) 5-fluorouracil alone).
  • Many (44 percent Stages I/II, 48.9 percent Stage III) required dose adjustments.
  • Bivariate analyses demonstrated that T stage (P=0.0019), completion of radiotherapy, and total radiotherapy dose (P=0.03) were all significantly associated with treatment failure.
  • On multivariate analyses, disease stage (P=0.05) and completion of radiotherapy (P=0.01) remained significant predictors of relapse-free survival.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Dis Colon Rectum. 2008 May;51(5):620
  • (PMID = 18180997.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Pucciarelli S, Capirci C, Emanuele U, Toppan P, Friso ML, Pennelli GM, Crepaldi G, Pasetto L, Nitti D, Lise M: Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer. Ann Surg Oncol; 2005 Feb;12(2):111-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer.
  • BACKGROUND: We investigated the relationship between pathologic T-stage and mesorectal metastases after preoperative chemoradiotherapy (CRT) for clinical stage II to III rectal carcinoma.
  • METHODS: The records of consecutive patients with clinical stage II to III carcinoma of the mid or low rectum who underwent surgery after CRT were reviewed.
  • Indications for preoperative CRT were cancer up to 11 cm from the anal verge, Eastern Cooperative Oncology Group performance status of 0 to 2, age 18 to 75 years, and clinical tumor-node-metastasis stage II or III.
  • The pretreatment tumor-node-metastasis stage was as follows: I, n = 1; II, n = 96; and III, n = 138.
  • According to the pT stage, the rate of node positivity was 2% for pT0, 15% for pT1, 17% for pT2, 38% for pT3, and 33% for pT4 cases.
  • On considering pT stage alone, the odds ratio was in the region of 10 for pT1/2 and >20 for pT3/4 patients.
  • CONCLUSIONS: In patients with pT0 after preoperative CRT for clinical stage II to III mid or low rectal cancer, the risk of nodal metastases is very low.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2005 Feb;12(2):95-7 [15827785.001]
  • (PMID = 15827790.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


12. Wrobel K, Wrobel K, Caruso JA: Epigenetics: an important challenge for ICP-MS in metallomics studies. Anal Bioanal Chem; 2009 Jan;393(2):481-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the early stage of instrumental development, total concentration was assessed in a variety of samples, yielding results, among others, for environmental, biological, and clinical samples.
  • Among a variety of epigenetic factors, essential nutrients, but also environmental toxins, have been shown to affect DNA methylation, modification of histone proteins, and RNA interference, all of them being implicated in cancer, cardiovascular disease, and several inherited conditions.
  • In this Trends article, the basic epigenetic concepts are introduced, followed by the early applications of ICP-MS classified as: (i) detection of (31)P as a natural element tag for DNA, (ii) analysis of DNA adducts with metal-based drugs, (iii) element species as epigenetic factors.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • Hazardous Substances Data Bank. PHOSPHORUS, ELEMENTAL .
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18979091.001).
  • [ISSN] 1618-2650
  • [Journal-full-title] Analytical and bioanalytical chemistry
  • [ISO-abbreviation] Anal Bioanal Chem
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Metals; 0 / Pharmaceutical Preparations; 27YLU75U4W / Phosphorus; 9007-49-2 / DNA; H6241UJ22B / Selenium; N712M78A8G / Arsenic
  • [Number-of-references] 38
  •  go-up   go-down


13. Kim SH, Park IJ, Joh YG, Hahn KY: Laparoscopic resection for rectal cancer: a prospective analysis of thirty-month follow-up outcomes in 312 patients. Surg Endosc; 2006 Aug;20(8):1197-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic resection for rectal cancer: a prospective analysis of thirty-month follow-up outcomes in 312 patients.
  • BACKGROUND: This study aimed to prospectively evaluate operative safety and mid-term oncologic outcomes of laparoscopic rectal cancer resection performed by a single surgeon.
  • 257 patients (82.4%) had tumors located below 12 cm from the anal verge.
  • Distribution of TNM stages was 0:I:II:III:IV = 4.2%:17.9%:32.4%:37.2%:8.3%.
  • With a mean follow-up of 30 months in the stage I-III patients, the local recurrence rate was 2.9%.
  • CONCLUSION: Laparoscopic resection of rectal cancer provided safe operative parameters and adequate mid-term oncologic outcomes.
  • When considering a high volume of advanced and low-lying cancers but rather narrow indication to radiotherapy, the 2.9% local recurrence rate seems promising data.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Surg Endosc. 2004 Oct;18(10):1457-62 [15791369.001]
  • [Cites] Arch Surg. 1998 Aug;133(8):894-9 [9711965.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1718-26 [15894098.001]
  • [Cites] Dis Colon Rectum. 2001 Apr;44(4):473-83; discussion 483-6 [11330574.001]
  • [Cites] Lancet. 2004 Apr 10;363(9416):1187-92 [15081650.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):260-8 [15273550.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):800-11 [9637543.001]
  • [Cites] Surg Endosc. 2005 Jun;19(6):757-66 [15868256.001]
  • [Cites] Br J Surg. 2001 Nov;88(11):1501-5 [11683749.001]
  • [Cites] Colorectal Dis. 2005 Jul;7(4):403-5 [15932567.001]
  • [Cites] Ann Surg. 2003 Mar;237(3):335-42 [12616116.001]
  • [Cites] Surgery. 1998 Oct;124(4):612-7; discussion 617-8 [9780979.001]
  • [Cites] Ann Surg. 1999 Oct;230(4):544-52; discussion 552-4 [10522724.001]
  • [Cites] Int J Colorectal Dis. 2005 Sep;20(5):428-33 [15800782.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Surg Endosc. 2002 Jun;16(6):989-95 [12163970.001]
  • [Cites] Br J Surg. 1994 Aug;81(8):1224-6 [7953369.001]
  • [Cites] Surg Gynecol Obstet. 1984 Jan;158(1):33-8 [6691164.001]
  • [Cites] Br J Surg. 2005 Feb;92(2):230-4 [15609379.001]
  • [Cites] Surg Endosc. 2004 Feb;18(2):281-9 [14691716.001]
  • (PMID = 16865622.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Staudacher C, Di Palo S, Tamburini AM, Vignali A, Orsenigo E: [The role of neoadjuvant radio-chemotherapy in the treatment of rectal cancer]. Ann Ital Chir; 2007 Nov-Dec;78(6):493-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of neoadjuvant radio-chemotherapy in the treatment of rectal cancer].
  • [Transliterated title] Il ruolo della radiochemioterapia neoadiuvante nel trattamento del tumore del retto.
  • OBJECTIVE: To evaluate oncological and surgical outcome of patients submitted to neoadjuvant therapy for advanced rectal cancer.
  • PATIENTS AND METHOD: One hundred thirty eight patients (86 male, 52 female, mean age 61.4 years), with tumour of lower (58; 42%), middle (66; 48%), upper rectum (14; 10%), showing a clinical stage II (23; 17%) or III (115; 83%) and with an average distance from anal verge of 6.5 cm, submitted to fractionated "long-course" RT with CT locally staged by US and MR before and after neoadjuvant therapy and operated on after 4-6 weeks by its end.
  • Pre-treatment clinical stage was not significant.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18510028.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


16. Fujita S, Yamamoto S, Akasu T, Moriya Y: Outcome of patients with clinical stage II or III rectal cancer treated without adjuvant radiotherapy. Int J Colorectal Dis; 2008 Nov;23(11):1073-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with clinical stage II or III rectal cancer treated without adjuvant radiotherapy.
  • BACKGROUND: To clarify the indications for preoperative adjuvant radiotherapy for rectal cancer, the outcome of patients who underwent curative surgery without adjuvant radiotherapy was investigated.
  • METHODS: A total of 817 consecutive patients who underwent curative surgery for clinical stage II or III rectal cancer without preoperative adjuvant radiotherapy between 1988 and 2002 were reviewed.
  • Univariate analysis showed that sex, pathological T classification (pT), clinical N classification (cN), pathological N classification (pN), tumor site, distance from the anal verge, type of surgery, pathological stage, a positive radical margin, lymphatic invasion, and venous invasion were significantly correlated with local recurrence.
  • Multivariate analysis of preoperative factors identified cN, distance from the anal verge, and sex as statistically significant risk factors for local recurrence.
  • In patients with rectal cancer located less than 5 cm from the anal verge and with positive cN, the local recurrence rate was more than 10%.
  • CONCLUSIONS: Patients with rectal cancer located less than 5 cm from the anal verge and with clinically positive lymph nodes should be given preoperative adjuvant radiotherapy.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Colorectal Dis. 2006 Jan;8(1):34-6 [16519635.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4620-5 [17008704.001]
  • [Cites] Dis Colon Rectum. 2006 Mar;49(3):345-52 [16532369.001]
  • [Cites] Dis Colon Rectum. 2007 Feb;50(2):156-67 [17180256.001]
  • [Cites] Semin Oncol. 2006 Dec;33(6 Suppl 11):S64-9 [17178291.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1847-58 [15774778.001]
  • [Cites] Dis Colon Rectum. 2005 Feb;48(2):218-26 [15711860.001]
  • [Cites] N Engl J Med. 2006 Sep 14;355(11):1114-23 [16971718.001]
  • [Cites] Br J Surg. 1982 Oct;69(10):613-6 [6751457.001]
  • [Cites] Dis Colon Rectum. 2006 Sep;49(9):1266-74 [16915510.001]
  • [Cites] Br J Surg. 2007 Oct;94(10):1278-84 [17579345.001]
  • [Cites] Ann Surg. 2005 Oct;242(4):502-10; discussion 510-1 [16192810.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):411-23 [15875292.001]
  • [Cites] Br J Surg. 2006 Dec;93(12):1519-25 [17054311.001]
  • [Cites] Radiology. 2003 May;227(2):371-7 [12732695.001]
  • [Cites] Br J Surg. 2003 Dec;90(12):1580-5 [14648739.001]
  • [Cites] Semin Oncol. 2006 Dec;33(6 Suppl 11):S70-4 [17178292.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8697-705 [16314629.001]
  • [Cites] Dis Colon Rectum. 2006 May;49(5):557-67 [16550319.001]
  • [Cites] Br J Surg. 2006 Oct;93(10):1215-23 [16983741.001]
  • [Cites] Br J Surg. 2006 Jul;93(7):860-5 [16710878.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):449-57 [11923599.001]
  • [Cites] Eur J Surg Oncol. 2006 Jun;32(5):520-6 [16600560.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6199-206 [16135487.001]
  • [Cites] Lancet. 1994 Sep 10;344(8924):707-11 [7915774.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):83-90 [17592295.001]
  • [Cites] Lancet. 1986 Nov 1;2(8514):996-9 [2430152.001]
  • (PMID = 18594841.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


17. Horisberger K, Treschl A, Mai S, Barreto-Miranda M, Kienle P, Ströbel P, Erben P, Woernle C, Dinter D, Kähler G, Hochhaus A, Post S, Willeke F, Wenz F, Hofheinz RD, MARGIT (Mannheimer Arbeitsgruppe für Gastrointestinale Tumoren): Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial. Int J Radiat Oncol Biol Phys; 2009 Aug 1;74(5):1487-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
  • PURPOSE: To evaluate the safety and efficacy of preoperative radiotherapy (RT) in combination with cetuximab, capecitabine, and irinotecan in patients with locally advanced rectal cancer.
  • METHODS AND MATERIALS: Patients with rectal cancer (clinical stage T3/4 or N+) were scheduled to receive cetuximab (400 mg/m(2) Day 1, 250 mg/m(2) Days 8, 15, 22, 29) in combination with weekly irinotecan 40 mg/m(2) and capecitabine 500 mg/m(2) twice daily (Days 1-38).
  • RESULTS: Fifty patients were enrolled; 88% showed T3 or T4 and 76% nodal-positive tumors with a median distance from the anal verge of 7.5 cm.
  • Main adverse events Grades 2/3/4 were (National Cancer Institute common toxicity criteria version 3.0, %): leukocytopenia 6/2/2, nausea/vomiting 4/2/0, diarrhea 34/30/0, proctitis 26/2/0, elevation of liver transaminases 8/10/0, and acnelike skin rash 46/6/0.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131187.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 7673326042 / irinotecan; PQX0D8J21J / Cetuximab; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


18. Choi GS, Park IJ, Kang BM, Lim KH, Jun SH: A novel approach of robotic-assisted anterior resection with transanal or transvaginal retrieval of the specimen for colorectal cancer. Surg Endosc; 2009 Dec;23(12):2831-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel approach of robotic-assisted anterior resection with transanal or transvaginal retrieval of the specimen for colorectal cancer.
  • The tumor stage was I in four, II in two, and III in seven patients.
  • CONCLUSION: Robotic-assisted laparoscopic methods were safe for AR in patients with colorectal cancer.
  • [MeSH-minor] Adult. Aged. Anal Canal. Female. Humans. Length of Stay. Male. Middle Aged. Vagina

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2001 Nov;25(11):1408-11 [11760744.001]
  • [Cites] Surg Endosc. 2002 Sep;16(9):1267-70 [12235507.001]
  • [Cites] Int J Gynaecol Obstet. 2005 Oct;91(1):27-31 [16051243.001]
  • [Cites] Fertil Steril. 2000 May;73(5):1040-2 [10785235.001]
  • [Cites] J Am Assoc Gynecol Laparosc. 2004 Feb;11(1):42-6 [15104829.001]
  • [Cites] Arch Surg. 2003 Jul;138(7):777-84 [12860761.001]
  • [Cites] Ann Surg Oncol. 2007 Nov;14(11):3168-73 [17763911.001]
  • [Cites] Dis Colon Rectum. 2002 Dec;45(12):1689-94; discussion 1695-6 [12473897.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2002 Feb;12(1):1-5 [12008756.001]
  • [Cites] Surg Endosc. 2003 Oct;17(10):1521-4 [12915974.001]
  • [Cites] Int J Colorectal Dis. 2008 Jul;23(7):703-7 [18379795.001]
  • [Cites] Surg Endosc. 2001 Sep;15(9):918-23 [11605106.001]
  • [Cites] Surg Endosc. 2006 Nov;20(11):1713-8 [17008953.001]
  • [Cites] Fertil Steril. 1996 Jan;65(1):193-7 [8557141.001]
  • [Cites] Dis Colon Rectum. 2004 Dec;47(12):2162-8 [15657669.001]
  • [Cites] J Urol. 2001 Jun;165(6 Pt 1):1964-6 [11371890.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2002 Feb;12(1):41-5 [12008761.001]
  • [Cites] Surgery. 2002 Jan;131(1 Suppl):S330-3 [11821833.001]
  • [Cites] Surg Endosc. 2002 Oct;16(10):1389-402 [12140630.001]
  • [Cites] Surg Endosc. 2008 Mar;22(3):792-7 [18027033.001]
  • [Cites] Surg Endosc. 2006 Oct;20(10):1521-5 [16897284.001]
  • [Cites] Surg Endosc. 2002 Dec;16(12):1691-6 [12140631.001]
  • [Cites] Heart Surg Forum. 2001;4(4):307-10 [11827857.001]
  • (PMID = 19440794.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Video-Audio Media
  • [Publication-country] Germany
  •  go-up   go-down


19. Filippi L, Cavallaro G, Fiorini P, Daniotti M, Benedetti V, Cristofori G, Araimo G, Ramenghi L, La Torre A, Fortunato P, Pollazzi L, la Marca G, Malvagia S, Bagnoli P, Ristori C, Dal Monte M, Bilia AR, Isacchi B, Furlanetto S, Tinelli F, Cioni G, Donzelli G, Osnaghi S, Mosca F: Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491. BMC Pediatr; 2010 Nov 18;10:83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS/DESIGN: Preterm newborns (gestational age at birth lower than 32 weeks) with stage 2 ROP (zone II-III without plus) will be randomized, according to their gestational age, to receive propranolol added to standard treatment (treatment adopted by the ETROP Cooperative Group) or standard treatment alone.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Archivio Istituzionale della Ricerca Unimi. Full text from AIR - Univ. Milan .
  • Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Retina. 2008 Mar;28(3 Suppl):S19-25 [18317339.001]
  • [Cites] Br J Ophthalmol. 2008 May;92(5):689-93 [18408080.001]
  • [Cites] Retina. 2008 Jun;28(6):831-8 [18536599.001]
  • [Cites] N Engl J Med. 2008 Jun 12;358(24):2649-51 [18550886.001]
  • [Cites] Prog Retin Eye Res. 2008 Jul;27(4):331-71 [18653375.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5177-82 [18708611.001]
  • [Cites] Growth Factors. 2008 Dec;26(6):325-30 [19021032.001]
  • [Cites] J Pharm Biomed Anal. 2008 Dec 15;48(5):1392-6 [18980824.001]
  • [Cites] Brain Behav Immun. 2009 Feb;23(2):267-75 [18996182.001]
  • [Cites] Pediatrics. 2009 Mar;123(3):e484-9 [19221153.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2009 Aug;297(2):R258-64 [19458283.001]
  • [Cites] Oncol Rep. 2009 Oct;22(4):825-30 [19724861.001]
  • [Cites] Nat Med. 1995 Oct;1(10):1024-8 [7489357.001]
  • [Cites] Arch Ophthalmol. 1996 Feb;114(2):150-4 [8573016.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4604-13 [8756616.001]
  • [Cites] Arch Ophthalmol. 1996 Oct;114(10):1219-28 [8859081.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):4-25 [9034784.001]
  • [Cites] Growth Factors. 1998;16(1):1-9 [9777366.001]
  • [Cites] J Biol Chem. 1999 Jun 4;274(23):16349-54 [10347193.001]
  • [Cites] Development. 2005 Apr;132(8):1855-62 [15790963.001]
  • [Cites] Pediatrics. 2005 Jul;116(1):15-23 [15995025.001]
  • [Cites] Auton Neurosci. 2005 Aug 31;121(1-2):33-9 [15961351.001]
  • [Cites] Circ Res. 2005 Nov 25;97(11):1182-9 [16239589.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):369-75 [16428474.001]
  • [Cites] Arch Ophthalmol. 2006 Feb;124(2):199-202 [16476889.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2744-9 [16381019.001]
  • [Cites] Nat Med. 2006 Aug;12(8):939-44 [16862152.001]
  • [Cites] Br J Ophthalmol. 2006 Nov;90(11):1378-82 [16914473.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10357-64 [17079456.001]
  • [Cites] Eur J Pharmacol. 2006 Dec 28;553(1-3):54-60 [17070516.001]
  • [Cites] Epilepsia. 2009 Dec;50(12):2658-62 [19682026.001]
  • [Cites] J Pediatr. 2010 Apr;156(4):550-5 [20056237.001]
  • [Cites] Arch Ophthalmol. 2010 Jun;128(6):663-71 [20385926.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2010 Jul;51(7):3709-13 [20181841.001]
  • [Cites] Pediatrics. 2009 Sep;124(3):e423-31 [19706583.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2011 Jan;52(1):155-70 [20739470.001]
  • [Cites] Pediatrics. 2003 Nov;112(5):1016-20 [14595040.001]
  • [Cites] Arch Ophthalmol. 2003 Dec;121(12):1684-94 [14662586.001]
  • [Cites] Physiology (Bethesda). 2004 Aug;19:176-82 [15304631.001]
  • [Cites] Pediatr Res. 2004 Nov;56(5):768-74 [15319463.001]
  • [Cites] Pediatrics. 1977 Nov;60(5):655-68 [578921.001]
  • [Cites] Am J Dis Child. 1980 Jul;134(7):707-8 [7395835.001]
  • [Cites] Nat Med. 1999 Dec;5(12):1390-5 [10581081.001]
  • [Cites] Pediatrics. 2000 Feb;105(2):295-310 [10654946.001]
  • [Cites] J Biol Chem. 2000 May 5;275(18):13802-11 [10788502.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2866-9 [11306460.001]
  • [Cites] FASEB J. 2001 May;15(7):1215-7 [11344092.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 8;98(10):5804-8 [11331770.001]
  • [Cites] Pharmacol Rev. 2001 Jun;53(2):319-56 [11356987.001]
  • [Cites] EMBO J. 2001 Jun 1;20(11):2768-78 [11387210.001]
  • [Cites] Arch Ophthalmol. 2001 Aug;119(8):1129-33 [11483078.001]
  • [Cites] Childs Nerv Syst. 2002 Apr;18(3-4):137-41 [11981620.001]
  • [Cites] Ophthalmology. 2002 May;109(5):928-34; discussion 935 [11986099.001]
  • [Cites] Ophthalmology. 2002 May;109(5):936-41 [11986101.001]
  • [Cites] Front Biosci. 2003 May 1;8:d1030-43 [12700061.001]
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):20681-6 [12670949.001]
  • [Cites] Breast Cancer Res Treat. 2003 Jul;80(1):63-70 [12889599.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4514-21 [14555525.001]
  • [Cites] Am J Dis Child. 1980 Sep;134(9):819-20 [6998280.001]
  • [Cites] Pediatrics. 1984 Jan;73(1):82-96 [6419199.001]
  • [Cites] Pediatrics. 1987 May;79(5):663-9 [3575019.001]
  • [Cites] Hypertension. 1988 Mar;11(3 Pt 2):II21-9 [2895072.001]
  • [Cites] Ophthalmology. 1991 Nov;98(11):1628-40 [1800923.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):843-5 [1279431.001]
  • [Cites] Endocrinology. 1993 Aug;133(2):848-59 [7688292.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1994 Jan;35(1):101-11 [7507904.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):905-9 [7846076.001]
  • [Cites] Circ Res. 1995 May;76(5):758-66 [7728992.001]
  • [Cites] Exp Eye Res. 2007 Jan;84(1):75-81 [17074321.001]
  • [Cites] Arch Ophthalmol. 2006 Dec;124(12):1711-8 [17159030.001]
  • [Cites] Neurochem Int. 2007 Jan;50(1):211-8 [17014930.001]
  • [Cites] Angiogenesis. 2007;10(2):133-40 [17332988.001]
  • [Cites] Ophthalmic Surg Lasers Imaging. 2007 May-Jun;38(3):233-7 [17552391.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 Nov;48(11):5276-81 [17962483.001]
  • [Cites] Early Hum Dev. 2008 Feb;84(2):107-13 [17513071.001]
  • [Cites] Early Hum Dev. 2008 Feb;84(2):77-82 [18234457.001]
  • (PMID = 21087499.001).
  • [ISSN] 1471-2431
  • [Journal-full-title] BMC pediatrics
  • [ISO-abbreviation] BMC Pediatr
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN18523491; ClinicalTrials.gov/ NCT01079715
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 9Y8NXQ24VQ / Propranolol
  • [Other-IDs] NLM/ PMC2993687
  •  go-up   go-down


20. Dai Y, Jiang JB, Bi DS, Jin ZT, Sun JZ, Hu SY: Preservation of the continence function after intersphincteric resection using a prolapsing technique in the patients with low rectal cancer and its clinical prognosis. Chin Med J (Engl); 2008 Oct 20;121(20):2016-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preservation of the continence function after intersphincteric resection using a prolapsing technique in the patients with low rectal cancer and its clinical prognosis.
  • BACKGROUND: The technique of intersphincteric resection of tumors combined with coloanal anastomosis has been used to avoid permanent colostomy for patients with a rectal cancer located < 5 cm from the anal verge.
  • This study aimed at assessing the preservation of continence function of the residual rectum and the clinical prognosis of patients with lower rectal cancer after intersphincteric resection using a prolapsing technique.
  • (1) pathological evidence of rectal cancer and the tumors within distal margins located 5 cm or less from the anus by preoperative endoscopic examination;.
  • From January 2000 to June 2004, 23 patients with low rectal cancer were included in this study.
  • The patients were followed for assessment of the function of the residual rectum and of cancer recurrence after the operations.
  • RESULTS: The median tumor distance from the anal margin was 4.5 (range 3.5 - 5.0) cm and the mean distal surgical margin 1.6 (range 1.0 - 2.0) cm.
  • Cancer was classified into Stage I (30.4%), Stage II (47.8%), and Stage III (21.7%) according to the TNM classification.
  • Anal manometer measurements showed a decrease of pressure during the resting time after intersphincteric resection and this change remained during the period of follow-up.
  • CONCLUSIONS: More residual rectum function after the surgery may be preserved by intersphincteric resection of low rectum cancer.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080267.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


21. Shanafelt TD, Call TG, Zent CS, LaPlant B, Bowen DA, Roos M, Secreto CR, Ghosh AK, Kabat BF, Lee MJ, Yang CS, Jelinek DF, Erlichman C, Kay NE: Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol; 2009 Aug 10;27(23):3808-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia.
  • PATIENTS AND METHODS: Previously untreated patients with asymptomatic Rai stage 0 to II CLL were eligible for participation.
  • Response was classified using the National Cancer Institute (NCI) Working Group (WG) Criteria.
  • A phase II trial to evaluate efficacy using 2,000 mg twice a day began in November 2007.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Biochem. 2000 Mar 15;279(2):164-9 [10706785.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3807-17 [18599795.001]
  • [Cites] Br J Cancer. 2001 Mar 23;84(6):844-50 [11259102.001]
  • [Cites] J Biol Chem. 2001 Apr 20;276(16):13322-30 [11278274.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2002;42:25-54 [11807163.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):381-5 [11809684.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):10-24 [11842384.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):854-61 [11843819.001]
  • [Cites] Arch Pharm Res. 2002 Oct;25(5):561-71 [12433185.001]
  • [Cites] Cancer Res. 2003 Feb 15;63(4):824-30 [12591733.001]
  • [Cites] Br J Haematol. 2003 Apr;121(2):287-95 [12694251.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1466-71 [12697868.001]
  • [Cites] Curr Treat Options Oncol. 2003 Jun;4(3):211-8 [12718798.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3312-9 [12960117.001]
  • [Cites] Biochem Pharmacol. 2003 Nov 1;66(9):1769-78 [14563487.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7563-70 [14633667.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8118-21 [14678963.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1202-10 [14576043.001]
  • [Cites] Toxicol In Vitro. 2004 Oct;18(5):555-61 [15251172.001]
  • [Cites] Blood. 2004 Aug 1;104(3):788-94 [14996703.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1567-74 [15090467.001]
  • [Cites] Hematol Oncol. 1988 Jan-Mar;6(1):7-12 [3277904.001]
  • [Cites] Br J Haematol. 1989 Jun;72(2):141-9 [2757960.001]
  • [Cites] Mayo Clin Proc. 1994 Apr;69(4):323-8 [8170175.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Jun;4(4):393-9 [7655336.001]
  • [Cites] Leukemia. 1996 Mar;10(3):456-9 [8642861.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Nature. 1997 Sep 11;389(6647):134-5 [9296488.001]
  • [Cites] J Natl Cancer Inst. 1997 Dec 17;89(24):1881-6 [9414176.001]
  • [Cites] Leuk Lymphoma. 1997 Nov;27(5-6):523-32 [9477135.001]
  • [Cites] N Engl J Med. 1998 May 21;338(21):1506-14 [9593789.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Aug 19;249(2):391-6 [9712707.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2059-64 [15781612.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4627-33 [15958649.001]
  • [Cites] Leuk Res. 2006 Jun;30(6):707-12 [16325256.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1227-38 [16731755.001]
  • [Cites] Cell Death Differ. 2006 Aug;13(8):1419-21 [16645636.001]
  • [Cites] Ann Intern Med. 2006 Sep 19;145(6):435-47 [16983131.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2804-10 [16809610.001]
  • [Cites] J Nutr. 2007 Jan;137(1 Suppl):223S-228S [17182830.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2144-50 [17404098.001]
  • [Cites] J Cell Physiol. 2007 Oct;213(1):252-60 [17477351.001]
  • [Cites] Life Sci. 2007 Jul 26;81(7):519-33 [17655876.001]
  • [Cites] Semin Cancer Biol. 2007 Oct;17(5):395-402 [17686632.001]
  • [Cites] Blood. 2008 Jan 15;111(2):846-55 [17928528.001]
  • [Cites] J Cell Biochem. 2008 Feb 1;103(2):509-19 [17570133.001]
  • [Cites] Br J Haematol. 2008 Mar;140(5):537-46 [18275431.001]
  • [Cites] Antioxid Redox Signal. 2008 Mar;10(3):475-510 [18154485.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5446-56 [18216293.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1923-30 [18577710.001]
  • [Cites] Cancer Lett. 2008 Oct 8;269(2):269-80 [18501505.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1830-8 [11251015.001]
  • (PMID = 19470922.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA113408; United States / NCI NIH HHS / CA / R01 CA136591; United States / NCI NIH HHS / CA / CA113408; United States / NCI NIH HHS / CA / CA6912
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Tea; 0 / polyphenon E; 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate
  • [Other-IDs] NLM/ PMC2727287
  •  go-up   go-down


22. Saleh F, Abdeen S: Pathobiological features of breast tumours in the State of Kuwait: a comprehensive analysis. J Carcinog; 2007;6:12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Breast cancer accounts for 30.3% of all cancer types in Kuwaiti women.
  • Grading of invasive carcinomas was done according to the modified Bloom-Richardson-Elston's method, and tumour stage was determined according to the criteria set by the American Joint Committee on Cancer.
  • They were mostly grade II or III, sized 2-5 or > 5 cm, had absent or scanty tumour lymphocytes, and were stage II or III.
  • The in situ tumours were mainly ductal carcinoma (DCIS) of which comedo and cribriform were the major histological subtypes.
  • CONCLUSION: Breast cancer in Kuwait seems to be more aggressive than what is currently seen in Europe, North America, Australia, and parts of Asia.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1998 Feb;11(2):155-68 [9504686.001]
  • [Cites] J Surg Oncol. 2004 Jun 1;86(3):134-40 [15170651.001]
  • [Cites] Breast Cancer Res Treat. 1998;51(3):195-208 [10068079.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):26-35 [15332092.001]
  • [Cites] Eur J Cancer Prev. 2004 Aug;13(4):307-17 [15554559.001]
  • [Cites] Am Surg. 2005 Jan;71(1):22-7; discussion 27-8 [15757052.001]
  • [Cites] Kaohsiung J Med Sci. 2005 May;21(5):197-202 [15960065.001]
  • [Cites] Breast Cancer Res. 2005;7(4):R541-54 [15987461.001]
  • [Cites] Br J Dermatol. 2005 Jul;153(1):18-21 [16029321.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3c):2535-42 [16080489.001]
  • [Cites] J Reprod Immunol. 2005 Oct;67(1-2):35-50 [16111767.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R598-604 [16168103.001]
  • [Cites] Acta Oncol. 1990;29(7):931-4 [1979748.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):944-8 [1988136.001]
  • [Cites] Acta Oncol. 1990;29(2):129-35 [2334566.001]
  • [Cites] Acta Oncol. 1989;28(6):807-10 [2611034.001]
  • [Cites] Aust N Z J Med. 1978 Dec;8(6):630-8 [285684.001]
  • [Cites] BMJ. 1988 Oct 15;297(6654):943-8 [3142562.001]
  • [Cites] Acta Pathol Jpn. 1984 Mar;34(2):229-39 [6331061.001]
  • [Cites] J Clin Oncol. 1984 Oct;2(10):1102-9 [6491696.001]
  • [Cites] Hum Pathol. 1983 Apr;14(4):368-72 [6832775.001]
  • [Cites] Hum Pathol. 1995 Aug;26(8):873-9 [7635449.001]
  • [Cites] Breast Cancer Res Treat. 1995 Aug;35(2):201-10 [7647342.001]
  • [Cites] Semin Diagn Pathol. 1994 Aug;11(3):208-14 [7831532.001]
  • [Cites] Anal Quant Cytol Histol. 1994 Jun;16(3):203-10 [7916848.001]
  • [Cites] Surgery. 1994 Oct;116(4):605-8; discussion 608-9 [7940156.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):23-33 [8083119.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):156-61 [8100443.001]
  • [Cites] Hematol Oncol Clin North Am. 1994 Feb;8(1):73-100 [8150784.001]
  • [Cites] Am J Surg. 1993 Mar;165(3):307-11 [8447534.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2894-904 [9256133.001]
  • [Cites] AJR Am J Roentgenol. 1998 Jan;170(1):97-104 [9423608.001]
  • [Cites] Stem Cells. 1998;16(6):413-28 [9831867.001]
  • [Cites] Oncol Rep. 1999 Jan-Feb;6(1):135-8 [9864416.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):2011-7 [10213514.001]
  • [Cites] Ontogenez. 1999 Mar-Apr;30(2):130-3 [10368823.001]
  • [Cites] Mod Pathol. 1999 Aug;12(8):827-34 [10463486.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):855-61 [10548312.001]
  • [Cites] Oncol Rep. 2000 Mar-Apr;7(2):295-8 [10671674.001]
  • [Cites] Am J Surg. 2000 Feb;179(2):81-5 [10773138.001]
  • [Cites] J Clin Pathol. 2000 Sep;53(9):688-96 [11041059.001]
  • [Cites] Int J Cancer. 2002 Apr 10;98(5):754-60 [11920647.001]
  • [Cites] Oncol Rep. 2002 Sep-Oct;9(5):1053-7 [12168072.001]
  • [Cites] Breast Cancer Res Treat. 2002 Dec;76(3):221-36 [12462383.001]
  • [Cites] Eur J Cancer. 2003 Mar;39(5):622-30 [12628841.001]
  • [Cites] Jpn J Clin Oncol. 2003 Feb;33(2):61-7 [12629055.001]
  • [Cites] Oncol Rep. 2003 Sep-Oct;10(5):1321-8 [12883701.001]
  • [Cites] Endocr Rev. 1992 Feb;13(1):3-17 [1313356.001]
  • [Cites] Br J Cancer. 1992 Oct;66(4):610-3 [1419596.001]
  • [Cites] Curr Opin Obstet Gynecol. 2004 Feb;16(1):49-55 [15128008.001]
  • [Cites] Breast Cancer Res Treat. 1998;52(1-3):305-19 [10066089.001]
  • (PMID = 17892570.001).
  • [ISSN] 1477-3163
  • [Journal-full-title] Journal of carcinogenesis
  • [ISO-abbreviation] J Carcinog
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2169224
  •  go-up   go-down


23. Hamada M, Ozaki K, Iwata J, Nishioka Y, Horimi T: A case of rectosigmoid cancer metastasizing to a fistula in ano. Jpn J Clin Oncol; 2005 Nov;35(11):676-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of rectosigmoid cancer metastasizing to a fistula in ano.
  • We herein report a case of rectosigmoid cancer metastasizing to a fistula in ano.
  • A 53-year-old man complaining of anal bleeding consulted another hospital.
  • He had been suffering from an anal fistula since 7 years.
  • On the left upper side of the skin surface around the anus a fistula end was seen as a hole that tunneled down into the back passage, although no hard tumor was palpable on the hole.
  • The post-operative pathological diagnosis was rectosigmoid cancer, Type 2, T2, N0, M0, stage II.
  • The anal fistula was a simple type and mucinous discharge was not observed.
  • On 23 February 2004, coring out the anal fistula was performed by the former hospital.
  • We diagnosed this tumor as metastatic adenocarcinoma from a rectosigmoid cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Anus Neoplasms / secondary. Rectal Fistula / pathology. Rectal Neoplasms / pathology. Sigmoid Neoplasms / pathology
  • [MeSH-minor] Anal Canal / pathology. Humans. Lymph Node Excision. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16275674.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


24. Joshi-Barve S, Amancherla K, Patil M, Bhatnagar A, Mathews S, Gobejishvili L, Cave M, McClain C, Barve S: Acrolein, a ubiquitous pollutant and lipid hydroperoxide product, inhibits antiviral activity of interferon-alpha: relevance to hepatitis C. Free Radic Biol Med; 2009 Jul 1;47(1):47-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and can lead to hepatocellular carcinoma and end-stage liver disease.
  • This study examines the effects of acrolein on (i) IFNalpha-mediated signaling and antiviral gene expression in cultured and primary human hepatocytes and (ii) HCV replication in an HCV-replicon system.

  • Genetic Alliance. consumer health - Hepatitis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACROLEIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Nutr Food Res. 2008 Jan;52(1):7-25 [18203133.001]
  • [Cites] Chem Res Toxicol. 2007 Sep;20(9):1315-20 [17655273.001]
  • [Cites] Cell Microbiol. 2006 Jun;8(6):907-22 [16681834.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):797-801 [16682255.001]
  • [Cites] J Hepatol. 2006 Aug;45(2):271-9 [16595158.001]
  • [Cites] World J Gastroenterol. 2006 Oct 14;12(38):6098-101 [17036378.001]
  • [Cites] Ann Intern Med. 2000 Feb 15;132(4):296-305 [10681285.001]
  • [Cites] Toxicol Sci. 2000 Sep;57(1):6-15 [10966506.001]
  • [Cites] Neurobiol Aging. 2001 Mar-Apr;22(2):187-94 [11182468.001]
  • [Cites] Hepatology. 2001 Jul;34(1):121-5 [11431742.001]
  • [Cites] Chem Res Toxicol. 2002 Feb;15(2):180-6 [11849044.001]
  • [Cites] Arch Intern Med. 2002 Apr 8;162(7):811-5 [11926856.001]
  • [Cites] N Engl J Med. 2002 Sep 26;347(13):975-82 [12324553.001]
  • [Cites] Gut. 2003 Jan;52(1):126-9 [12477773.001]
  • [Cites] Mol Cell Biochem. 2002 Nov;240(1-2):83-98 [12487375.001]
  • [Cites] Liver Transpl. 2003 Apr;9(4):331-8 [12682882.001]
  • [Cites] Endocr J. 2003 Feb;50(1):61-7 [12733710.001]
  • [Cites] Cell Death Differ. 2003 Jul;10(7):772-81 [12815460.001]
  • [Cites] Free Radic Res. 2003 Jul;37(7):781-5 [12911275.001]
  • [Cites] Hepatology. 2003 Nov;38(5):1178-87 [14578856.001]
  • [Cites] Antioxid Redox Signal. 2004 Feb;6(1):19-24 [14713333.001]
  • [Cites] Ann Intern Med. 2004 Mar 16;140(6):465-79 [15023713.001]
  • [Cites] Gut. 2004 May;53(5):744-9 [15082595.001]
  • [Cites] Neurochem Int. 2004 Jun;44(7):475-86 [15209416.001]
  • [Cites] World J Gastroenterol. 2004 Oct 15;10(20):2963-6 [15378774.001]
  • [Cites] Toxicology. 2004 Nov 15;204(2-3):209-18 [15388247.001]
  • [Cites] Anal Biochem. 1987 May 15;163(1):9-15 [3619033.001]
  • [Cites] J Clin Pathol. 1997 May;50(5):401-6 [9215123.001]
  • [Cites] Free Radic Biol Med. 1998 May;24(7-8):1235-41 [9626579.001]
  • [Cites] J Hepatol. 1998 Jun;28(6):930-8 [9672166.001]
  • [Cites] Annu Rev Biochem. 1998;67:227-64 [9759489.001]
  • [Cites] J Neurochem. 1999 Feb;72(2):751-6 [9930749.001]
  • [Cites] J Hepatol. 1999 May;30(5):774-82 [10365801.001]
  • [Cites] Nature. 2005 Aug 18;436(7053):953-60 [16107835.001]
  • [Cites] Nature. 2005 Aug 18;436(7053):967-72 [16107837.001]
  • [Cites] J Allergy Clin Immunol. 2005 Oct;116(4):916-22 [16210070.001]
  • [Cites] Free Radic Biol Med. 2007 Feb 1;42(3):353-62 [17210448.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Dec;21(12):1821-5 [17074020.001]
  • [Cites] Br J Cancer. 2006 Mar 13;94(5):737-9 [16465190.001]
  • [Cites] Curr Hypertens Rep. 2007 Mar;9(1):66-72 [17362674.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):1319-25 [17363696.001]
  • [Cites] J Biol Chem. 2007 Jul 13;282(28):20059-63 [17502367.001]
  • [Cites] Chem Res Toxicol. 2007 Jul;20(7):986-90 [17559234.001]
  • [Cites] Minerva Gastroenterol Dietol. 2006 Jun;52(2):157-74 [16557187.001]
  • [Cites] Ann N Y Acad Sci. 2008 Apr;1126:185-9 [18448814.001]
  • (PMID = 19345260.001).
  • [ISSN] 1873-4596
  • [Journal-full-title] Free radical biology & medicine
  • [ISO-abbreviation] Free Radic. Biol. Med.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / K01 ES017105; United States / NIAAA NIH HHS / AA / R01 AA014371; United States / NIAAA NIH HHS / AA / R01 AA014371-05; United States / NIEHS NIH HHS / ES / T32 ES011564
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Air Pollutants; 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / STAT1 Transcription Factor; 0 / STAT1 protein, human; 0 / STAT2 Transcription Factor; 0 / STAT2 protein, human; 0 / peginterferon alfa-2a; 30IQX730WE / Polyethylene Glycols; 76543-88-9 / interferon alfa-2a; 7864XYD3JJ / Acrolein
  • [Other-IDs] NLM/ NIHMS123380; NLM/ PMC3947765
  •  go-up   go-down


25. Fallai C, Cerrotta A, Valvo F, Badii D, Olmi P: Anal carcinoma of the elderly treated with radiotherapy alone or with concomitant radio-chemotherapy. Crit Rev Oncol Hematol; 2007 Mar;61(3):261-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma of the elderly treated with radiotherapy alone or with concomitant radio-chemotherapy.
  • PURPOSE: To analyse the results achieved with radio-chemotherapy (RTCT) or radiotherapy alone (RT) in elderly patients (pts) affected with squamous cell anal cancer.
  • There were 9 stage I, 29 stage II, 11 stage IIIa and 13 stage IIIb.
  • RESULTS: Stage II fared significantly better than stage III in terms of locoregional control (LRC) but not overall survival (OS).
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085056.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


26. Tournier-Rangeard L, Peiffert D, Lafond C, Mege A, Metayer Y, Marchesi V, Buchheit I, Uwer L, Conroy T, Kaminsky MC: [Long-term results and prognostic factors of squamous cell carcinoma of the anal canal treated by irradiation]. Cancer Radiother; 2007 Jun;11(4):169-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results and prognostic factors of squamous cell carcinoma of the anal canal treated by irradiation].
  • [Transliterated title] Résultats à long terme et facteurs pronostiques des carcinomes épidermoïdes du canal anal traités par irradiation.
  • PURPOSE: To analyze the prognostic factors of loco regional control (LRC), specific survival (SS) and sphincter conservation (SC) of patients treated by curative and conservative irradiation for an epidermoid cancer of anal canal in our institution.
  • Forty-three pts were stage I, 154 stage II, 31 stage IIIA and 53 stage IIIB.
  • Five-years-LRC were 71.5% (88% for stage I, 69% for stage II, 77%, for stage IIIA and 60% for stage IIIB).
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17400501.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


27. Wang JP, Wu XJ, Song XM, Wang L, Huang MJ, Lan P: [Changes of sphincter preserving rate in lower rectal cancer and analysis of their related factors]. Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Mar;9(2):107-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changes of sphincter preserving rate in lower rectal cancer and analysis of their related factors].
  • OBJECTIVE: To analyze the factors related to sphincter preserving(SP) operation for lower rectal cancer.
  • METHODS: Clinicopathological data of 316 patients with lower rectal cancer 1-5 cm from the anorectal line who underwent surgical resection from Aug.
  • 1998) to 76.2 % in period II (Jan. 1999-Nov. 2005)(P=0.000).
  • Significant differences were detected between the two period in sex, volume of blood transfusion, Dukes' stage (P< 0.05).
  • [MeSH-major] Anal Canal / surgery. Rectal Neoplasms / surgery. Rectum / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16555145.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


28. Itoh H, Iwasaki M, Hanaoka T, Sasaki H, Tanaka T, Tsugane S: Urinary bisphenol-A concentration in infertile Japanese women and its association with endometriosis: A cross-sectional study. Environ Health Prev Med; 2007 Nov;12(6):258-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Median urinary BPA concentration in women with stage 0-1 endometriosis (0.74 μg/g creatinine) did not significantly differ from that in those with stage II-IV endometriosis (0.93 μg/g creatinine) (p for difference=0.24).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Fertil Steril. 2004 Dec;82(6):1501-8 [15589850.001]
  • [Cites] Environ Mol Mutagen. 2006 Oct;47(8):571-8 [16795089.001]
  • [Cites] Environ Health Prev Med. 2004 Jan;9(1):22-6 [21432334.001]
  • [Cites] Sci Total Environ. 2006 Apr 15;359(1-3):90-100 [16546516.001]
  • [Cites] Shokuhin Eiseigaku Zasshi. 2001 Apr;42(2):71-8 [11486386.001]
  • [Cites] Environ Health Perspect. 2004 Mar;112(3):331-8 [14998749.001]
  • [Cites] Environ Res. 2005 Sep;99(1):118-25 [15927178.001]
  • [Cites] Int J Hyg Environ Health. 2005;208(4):237-45 [16078637.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2004 Apr;18(2):177-200 [15157637.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Nov 25;780(2):365-70 [12401363.001]
  • [Cites] Environ Sci. 2006;13(1):15-29 [16685249.001]
  • [Cites] Anal Chem. 2005 Aug 15;77(16):5407-13 [16097788.001]
  • [Cites] Environ Health Perspect. 2005 Apr;113(4):391-5 [15811827.001]
  • [Cites] Nihon Eiseigaku Zasshi. 2004 Nov;59(4):403-8 [15626028.001]
  • [Cites] Ann N Y Acad Sci. 2002 Mar;955:11-22; discussion 34-6, 396-406 [11949940.001]
  • [Cites] Environ Health Perspect. 2003 Jan;111(1):101-4 [12515686.001]
  • [Cites] Fertil Steril. 1985 Mar;43(3):351-2 [3979573.001]
  • [Cites] Chem Res Toxicol. 2002 Oct;15(10):1281-7 [12387626.001]
  • [Cites] Obstet Gynecol Clin North Am. 2003 Mar;30(1):1-19, vii [12699255.001]
  • [Cites] Nihon Koshu Eisei Zasshi. 1991 Aug;38(8):567-74 [1747547.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Dec 12;312(2):441-8 [14637157.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Jun 5;820(1):49-57 [15866492.001]
  • [Cites] Anal Bioanal Chem. 2005 Oct;383(4):638-44 [16132150.001]
  • [Cites] Shokuhin Eiseigaku Zasshi. 2004 Dec;45(6):339-43 [15794093.001]
  • (PMID = 21432072.001).
  • [ISSN] 1342-078X
  • [Journal-full-title] Environmental health and preventive medicine
  • [ISO-abbreviation] Environ Health Prev Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2723486
  • [Keywords] NOTNLM ; HPLC-MS/MS / endocrine disruptor / epidemiology / urine / xenoestrogen
  •  go-up   go-down


29. Rivera R, Barboglio PG, Hellinger M, Gousse AE: Staging rectourinary fistulas to guide surgical treatment. J Urol; 2007 Feb;177(2):586-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Etiology was rectal injury during open radical prostatectomy in 5 patients, laparoscopic prostatectomy in 1, radiation induced fistula for prostate cancer treatment (brachytherapy and external beam radiation therapy) in 2, neoadjuvant external beam radiation therapy in 2, ischial decubitus ulcer in 3 with spinal cord injury, and cryotherapy and external beam radiation therapy in 1.
  • Cases were staged as stage I--low (less than 4 cm from anal verge and nonirradiated), stage II--high (more than 4 cm from anal verge and nonirradiated), stage III--small (less than 2 cm irradiated fistula), stage IV--large (more than 2 cm irradiated fistula) and stage V--large (ischial decubitus fistula).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222638.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Coucke PA, Notter M, Matter M, Fasolini F, Calmes JM, Schlumpf R, Schwegler N, Stamm B, Phuoc Do H, Bouzourene H: Effect of timing of surgery on survival after preoperative hyperfractionated accelerated radiotherapy (HART) for locally advanced rectal cancer (LARC): is it a matter of days? Acta Oncol; 2006;45(8):1086-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of timing of surgery on survival after preoperative hyperfractionated accelerated radiotherapy (HART) for locally advanced rectal cancer (LARC): is it a matter of days?
  • We intend to analyse retrospectively whether the time interval ("gap duration" = GD) between preoperative radiotherapy and surgery in locally advanced rectal cancer (LARC) has an impact on overall survival (OS), cancer specific survival (CSS), disease free survival (DFS) and local control (LC).
  • In multivariate analysis, the following factors independently predict outcome; for OS: age, GD, circumferential margin (CM) and nodal stage (ypN); for CSS: GD, ypN and vascular invasion (VI); for DFS: CEA, distance to anal verge, GD, ypN and VI; for LC: CM only.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • ORBi (University of Liege). Free full Text at ORBi .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Oncol. 2006;45(8):1013-7 [17118832.001]
  • (PMID = 17118844.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


31. Liang JT, Lai HS, Lee PH: Multimedia article. Laparoscopic abdominoperineal resection for lower rectal cancers: how do we do it? Surg Endosc; 2006 Apr;20(4):695-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The appropriateness of the laparoscopic approach for the resection of rectal cancer has been controversial, although it is well established in colon cancer.
  • This is a phase II study of laparoscopic abdominoperineal resection (APR) in the treatment of lower rectal cancers.
  • METHODS: Patients with lower rectal adenocarcinoma located within 6 cm above the anal verge were recruited and subjected to laparoscopic APR.
  • Physical status (American Society of Anesthesiology classification) was class I in 12, class II in eight, and class III in two patients.
  • Two patients were in pathologic TNM stage I, 14 in stage II, and six in stage III.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Dis Colon Rectum. 2002 Nov;45(11):1481-5 [12432295.001]
  • [Cites] World J Surg. 2002 Mar;26(3):377-83 [11865378.001]
  • [Cites] Lancet. 2004 Apr 10;363(9416):1187-92 [15081650.001]
  • [Cites] J Am Coll Surg. 1998 Jul;187(1):46-54; discussion 54-5 [9660024.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2000 Feb;10(1):47-53 [10706303.001]
  • [Cites] World J Surg. 2003 Feb;27(2):190-6 [12616435.001]
  • [Cites] Ann Surg. 1967 Sep;166(3):420-7 [6039601.001]
  • (PMID = 16502195.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article; Video-Audio Media
  • [Publication-country] Germany
  •  go-up   go-down


32. Zamboni BA, Yothers G, Choi M, Fuller CD, Dignam JJ, Raich PC, Thomas CR Jr, O'Connell MJ, Wolmark N, Wang SJ: Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07. J Clin Oncol; 2010 May 20;28(15):2544-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07.
  • PURPOSE: Colon cancer overall survival (OS) is usually computed from the time of diagnosis.
  • We extend the concept of CS to condition on the set of patients alive, recurrence-free, and second primary cancer-free (disease-free survival [OS|DFS]).
  • PATIENTS AND METHODS: Using data from National Surgical Adjuvant Breast and Bowel Project trials C-03 through C-07, 5-year OS|DFS was calculated on patients who were disease free up to 5 years after diagnosis, stratified by age, stage, nodal status, and performance status (PS).
  • RESULTS: For stage II, OS|DFS improved from 87% to 92% at 5 years.
  • For stage III, OS|DFS improved from 69% to 88%.
  • Patients with a PS of 0 or 1 demonstrated a small improvement; those with a PS of 2 did not (64% to 58%).
  • CONCLUSION: Prognosis improves over time for almost all groups of patients with colon cancer, especially those with positive nodes.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3553-9 [10550154.001]
  • [Cites] Lifetime Data Anal. 2008 Dec;14(4):447-63 [18836831.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2211-9 [11596040.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3035-40 [12915592.001]
  • [Cites] Surg Neurol. 2003 Nov;60(5):402-6; discussion 406 [14572960.001]
  • [Cites] Oncologist. 2003;8(6):541-52 [14657533.001]
  • [Cites] Eur J Cancer. 2004 May;40(8):1233-43 [15110888.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]
  • [Cites] Semin Surg Oncol. 1994 Jan-Feb;10(1):2-6 [8115782.001]
  • [Cites] Cancer. 1995 Jul 15;76(2):237-42 [8625098.001]
  • [Cites] J Clin Epidemiol. 1997 Nov;50(11):1289-96 [9393385.001]
  • [Cites] Dis Colon Rectum. 1998 Sep;41(9):1097-106 [9749492.001]
  • [Cites] J Natl Cancer Inst. 1998 Dec 2;90(23):1810-6 [9839521.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):485-91 [10023719.001]
  • [Cites] Breast Cancer Res Treat. 1998;51(3):239-53 [10068082.001]
  • [Cites] Chest. 1999 Sep;116(3):697-703 [10492274.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8664-70 [16260700.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2059-64 [16648506.001]
  • [Cites] Cancer. 2006 May 15;106(10):2165-70 [16586498.001]
  • [Cites] Oncologist. 2006 Jun;11(6):624-9 [16794241.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1331-43 [17326199.001]
  • [Cites] J Thorac Oncol. 2007 Mar;2(3):180-90 [17410040.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2198-204 [17470851.001]
  • [Cites] Ann Oncol. 2007 Aug;18(8):1408-13 [17693654.001]
  • [Cites] Gastric Cancer. 2007;10(3):153-8 [17922092.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):203-9 [18329082.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):257-64 [11263506.001]
  • (PMID = 20406942.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10CA-69974; United States / NCI NIH HHS / CA / U10 CA012027; United States / NCI NIH HHS / CA / U10 CA069651; United States / NCI NIH HHS / CA / U10CA-37377; United States / NCI NIH HHS / CA / U10 CA069974; United States / NCI NIH HHS / CA / U10CA-12027; United States / NCI NIH HHS / CA / U10 CA037377; United States / NCI NIH HHS / CA / U10CA-69651
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2881729
  •  go-up   go-down


33. Liang B, Wang S, Zhu XG, Yu YX, Cui ZR, Yu YZ: Increased expression of mitogen-activated protein kinase and its upstream regulating signal in human gastric cancer. World J Gastroenterol; 2005 Feb 7;11(5):623-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of mitogen-activated protein kinase and its upstream regulating signal in human gastric cancer.
  • AIM: To investigate the expression of mitogen-activated protein kinases (MAPKs) and its upstream protein kinase in human gastric cancer and to evaluate the relationship between protein levels and clinicopathological parameters.
  • METHODS: Western blot was used to measure the expression of extracellular signal-regulated kinase (ERK)-1, ERK-2, ERK-3, p38 and mitogen or ERK activated protein kinaseMEK-1 proteins in surgically resected gastric carcinoma, adjacent normal mucosa and metastatic lymph nodes from 42 patients.
  • RESULTS: Compared with normal tissues, the protein levels of ERK-1 (integral optical density value 159 526+/-65 760 vs 122 807+/-65 515, P = 0.001), ERK-2 (168 471+/-95 051 vs 120 469+/-72 874, P<0.001), ERK-3 (118 651+/-71 513 vs 70 934+/-68 058, P<0.001), P38 (104 776+/-51 650 vs 82 930+/-40 392, P = 0.048) and MEK-1 (116 486+/-45 725 vs 101 434+/-49 387, P = 0.027) were increased in gastric cancer tissues.
  • Overexpression of ERK-3 was correlated to TNM staging (average ratio of integral optic density (IOD)(tumor): IOD(normal) in TNM I, II, III, IV tumors was 1.43+/-0.34, 5.08+/-3.74, 4.99+/-1.08, 1.44+/-1.02, n = 42, P = 0.023) and serosa invasion (4.31+/-4.34 vs 2.00+/-2.03, P = 0.037).
  • In poorly differentiated cancers (n = 33), the protein levels of ERK-1 and ERK-2 in stage III and IV tumors were higher than those in stage I and II tumors (2.64+/-3.01 vs 1.01+/-0.33, P = 0.022; 2.05+/-1.54 vs 1.24+/-0.40, P = 0.030).
  • Gastric cancer tissues with either lymph node involvement (2.49+/-2.91 vs 1.03+/-0.36, P = 0.023; 1.98+/-1.49 vs 1.24+/-0.44, P = 0.036) or serosa invasion (2.39+/-2.82 vs 1.01+/-0.35, P = 0.022; 1.95+/-1.44 vs 1.14+/-0.36, P = 0.015) expressed higher protein levels of ERK-1 and ERK-2.
  • In Borrmann II tumors, expression of ERK-2 and ERK-3 was increased compared with Borrmann III tumors (2.57+/-1.86 vs 1.23+/-0.60, P = 0.022; 5.50+/-5.05 vs 1.83+/-1.21, P = 0.014).
  • The expression of MEK-1 in gastric cancer cells metastasized to lymph nodes was higher than that of the primary site.
  • MEK-1 is also overexpressed in gastric cancer, particularly in metastatic lymph nodes.
  • Upregulation of MAPK signal transduction pathways may play an important role in tumorigenesis and metastatic potential of gastric cancer.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15655810.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 6; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 2.7.12.2 / MAP Kinase Kinase 1
  • [Other-IDs] NLM/ PMC4250727
  •  go-up   go-down


34. Qiu JG, Fan J, Liu YK, Zhou J, Dai Z, Huang C, Tang ZY: Screening and detection of portal vein tumor thrombi-associated serum low molecular weight protein biomarkers in human hepatocellular carcinoma. J Cancer Res Clin Oncol; 2008 Mar;134(3):299-305
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening and detection of portal vein tumor thrombi-associated serum low molecular weight protein biomarkers in human hepatocellular carcinoma.
  • PURPOSE: Serum low molecular weight protein biomarkers might be important in relation to portal vein tumor thrombi (PVTT) in hepatocellular carcinoma (HCC).
  • By using two-dimensional gel electrophoresis (2-DE) in which the first dimension was 16% SDS-PAGE, serum protein images of 3 groups were analyzed by Image Master Software.
  • Compared with the healthy group, apolipoprotein A-I, lipoprotein CIII, transthyretin and DNA topoisomerase II were down regulated in HCC groups while haptoglobin-2 was over expressed.
  • CONCLUSION: The expression of low MW serum protein changes obviously in the beginning and progressive stage of HCC, and differentially expressed low MW proteins might be the potential biomarkers in early prognostication and surveillance of treatment for HCC and PVTT.
  • [MeSH-major] Biomarkers, Tumor / blood. Blood Proteins / analysis. Carcinoma, Hepatocellular / diagnosis. Liver Neoplasms / diagnosis. Portal Vein. Thrombosis / diagnosis

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1151-9 [12142367.001]
  • [Cites] J Surg Oncol. 2005 Aug 1;91(2):95-6 [16028278.001]
  • [Cites] J Clin Chem Clin Biochem. 1986 Mar;24(3):161-6 [2872262.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 2005 Apr 1;43(7):433-5 [15854367.001]
  • [Cites] Proteomics. 2005 Nov;5(17):4581-8 [16240287.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2404-8 [8096341.001]
  • [Cites] Anal Biochem. 1987 Nov 1;166(2):368-79 [2449095.001]
  • [Cites] Br J Cancer. 2004 Jul 5;91(1):129-40 [15199385.001]
  • [Cites] Electrophoresis. 2000 Apr;21(6):1037-53 [10786879.001]
  • [Cites] Proteomics. 2005 Dec;5(18):4964-72 [16252306.001]
  • [Cites] Circ Res. 2005 Jun 24;96(12 ):1221-32 [15976321.001]
  • [Cites] Adv Exp Med Biol. 1995;376:231-8 [8597253.001]
  • [Cites] Liver. 1988 Apr;8(2):65-74 [2452953.001]
  • [Cites] Lung Cancer. 2001 May;32(2):117-28 [11325482.001]
  • [Cites] Proteomics. 2003 Jul;3(7):1345-64 [12872236.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2803-8 [16385567.001]
  • [Cites] Proteomics. 2003 May;3(5):666-74 [12748946.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2B):1113-9 [12168909.001]
  • [Cites] Vox Sang. 2002 Aug;83 Suppl 1:315-9 [12617161.001]
  • (PMID = 17828420.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins
  •  go-up   go-down


35. Caron J, Mangé A, Guillot B, Solassol J: Highly sensitive detection of melanoma based on serum proteomic profiling. J Cancer Res Clin Oncol; 2009 Sep;135(9):1257-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 108 serum samples from 30 early-stage [American Joint Committee on Cancer (AJCC) stage I or II] and 30 advanced-stage (AJCC stage III or IV) melanoma patients and 48 healthy volunteers were analyzed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) utilizing protein chip technology and artificial neural networks.
  • RESULTS: In a first step, a multiprotein classifier was built using a training set of 30 pathologically confirmed melanoma and 24 healthy volunteer serum samples, resulting in good classification accuracy for correct diagnosis and stage classification assignment.
  • Subsequently, our multiprotein classifier was tested in an independent validation set of 30 melanoma and 24 non-cancer serum samples patients, maintained in a good diagnostic accuracy of 98.1% (sensitivity 96.7%, specificity 100%), and 100% stage I/II classification assignment.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 May 5;819(1):59-66 [15797521.001]
  • [Cites] Anal Biochem. 2005 Mar 1;338(1):26-31 [15707932.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):577-83 [11208853.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1891-6 [10561230.001]
  • [Cites] Artif Intell Med. 2004 Oct;32(2):71-83 [15364092.001]
  • [Cites] Proteomics. 2005 Aug;5(13):3467-74 [16052624.001]
  • [Cites] Cancer. 2003 Apr 1;97(7):1737-45 [12655531.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5088-93 [16051955.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:317-22 [15251977.001]
  • [Cites] Gynecol Oncol. 2007 Dec;107(3):526-31 [17920110.001]
  • [Cites] Melanoma Res. 2005 Dec;15(6):515-22 [16314737.001]
  • [Cites] Clin Biochem. 2004 Jul;37(7):512-8 [15234232.001]
  • [Cites] Expert Rev Proteomics. 2006 Jun;3(3):311-20 [16771703.001]
  • [Cites] J Biopharm Stat. 2002 Feb;12(1):1-19 [12146717.001]
  • [Cites] Curr Opin Mol Ther. 2000 Dec;2(6):643-50 [11249741.001]
  • [Cites] Neural Comput. 1998 Jul 28;10(6):1455-80 [9698353.001]
  • [Cites] Cancer Res. 1993 Oct 15;53(20):4927-32 [8104688.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3635-48 [11504745.001]
  • [Cites] Ann Oncol. 2003 Jun;14(6):946-57 [12796034.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6D):5041-4 [11326664.001]
  • [Cites] Melanoma Res. 2002 Jun;12(3):245-53 [12140381.001]
  • [Cites] Methods Mol Biol. 2008;428:125-40 [18287771.001]
  • [Cites] Cancer. 1993 Nov 15;72(10):3091-8 [8221576.001]
  • [Cites] Clin Chem. 2005 Jan;51(1):102-12 [15613711.001]
  • (PMID = 19288131.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins; 0 / Proteome
  •  go-up   go-down


36. Ferrigno R, Novaes PE, Silva ML, Nishimoto IN, Nakagawa WT, Rossi BM, Ferreira Fde O, Lopes A: Neoadjuvant radiochemotherapy in the treatment of fixed and semi-fixed rectal tumors. Analysis of results and prognostic factors. Radiat Oncol; 2006;1:5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To report the retrospective analysis of patients with locally advanced rectal cancer treated with neodjuvant radiochemotherapy.
  • In 71 patients (70.3%) the primary tumor was located up to 6 cm from the anal verge and in 30 (29.7%) from 6.5 cm to 10 cm.
  • Age, gender, tumor fixation, tumor distance from the anal verge, clinical response, surgical technique, and postoperative TNM stage were the prognostic factors analyzed for overall survival (OS), disease-free survival (DFS), and local control (LC) at five years.
  • Patients with tumors more than 6 cm above the anal verge had better LC (93% Vs 69%; p = 0.04).
  • The postoperative TNM stage was a significant factor for DFS (I:64.1%, II:69.6%, III:35.2%, IV:11.1%; p < 0.001) and for LC (I:75.7%, II: 92.9%, III:54.1%, IV:100%; p = 0.005).

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Radiother. 2004 Oct;8(5):297-304 [15561595.001]
  • [Cites] Dis Colon Rectum. 2004 Nov;47(11):1798-807 [15622571.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):665-77 [15708244.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1129-35 [15752893.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1847-58 [15774778.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1371-7 [15817339.001]
  • [Cites] Ann Surg. 2005 May;241(5):829-36; discussion 836-8 [15849519.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2396 [10561302.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):883-8 [10705009.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):713-8 [10837955.001]
  • [Cites] JAMA. 2000 Aug 23-30;284(8):1008-15 [10944647.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):843-56 [11020583.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1075-80 [11072165.001]
  • [Cites] Ann Surg Oncol. 2000 Dec;7(10):727-31 [11129419.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1779-86 [11251009.001]
  • [Cites] Ann Surg Oncol. 2001 Mar;8(2):163-9 [11258782.001]
  • [Cites] Am J Clin Oncol. 2001 Apr;24(2):107-12 [11319280.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):311-8 [11352304.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):659-63 [11395233.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):176-83 [11516868.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):896-902 [11550163.001]
  • [Cites] Ann Surg Oncol. 2001 Dec;8(10):801-6 [11776494.001]
  • [Cites] J Am Coll Surg. 2002 Feb;194(2):131-5; discussion 135-6 [11848629.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):294-303 [11872273.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):493-8 [11923604.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):664-74 [12062610.001]
  • [Cites] Ann Surg Oncol. 2002 Jul;9(6):568-73 [12095973.001]
  • [Cites] Ann Surg. 2002 Jul;236(1):75-81 [12131088.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1460-5 [12459370.001]
  • [Cites] Cancer. 2003 Jan 15;97(2):517-24 [12518377.001]
  • [Cites] Dis Colon Rectum. 2003 Feb;46(2):192-202 [12576893.001]
  • [Cites] Dis Colon Rectum. 2003 Mar;46(3):298-304 [12626903.001]
  • [Cites] Dis Colon Rectum. 2003 Apr;46(4):448-53 [12682535.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):84-9 [12909219.001]
  • [Cites] Dis Colon Rectum. 2003 Sep;46(9):1189-93 [12972962.001]
  • [Cites] Dis Colon Rectum. 2003 Sep;46(9):1194-9 [12972963.001]
  • [Cites] Semin Surg Oncol. 2003;21(4):261-4 [14648784.001]
  • [Cites] Semin Surg Oncol. 2003;21(4):265-70 [14648785.001]
  • [Cites] Eur J Cancer. 2004 Jan;40(2):219-24 [14728936.001]
  • [Cites] Tumori. 2004 May-Jun;90(3):303-9 [15315310.001]
  • [Cites] Dis Colon Rectum. 2004 Aug;47(8):1323-30 [15484346.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] J Clin Oncol. 1992 Aug;10(8):1218-24 [1634912.001]
  • [Cites] Cancer. 1993 Jun 1;71(11):3486-92 [8490898.001]
  • [Cites] Oncology (Williston Park). 1989 May;3(5):137-42; discussion 142, 146-8 [2577881.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):169-75 [8083110.001]
  • [Cites] Radiother Oncol. 1994 Aug;32(2):116-23 [7972904.001]
  • [Cites] Cancer Invest. 1995;13(1):96-107 [7834479.001]
  • [Cites] Cancer. 1995 May 1;75(9):2269-75 [7712435.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1409-16 [7751886.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1473-5 [7635791.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):281-7 [9069298.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):289-95 [9069299.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):893-900 [15936575.001]
  • [Cites] Semin Oncol. 1995 Dec;22(6):611-24 [8539636.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jul 15;35(5):1039-48 [8751414.001]
  • [Cites] Cancer. 1996 Sep 1;78(5):968-76 [8780533.001]
  • [Cites] Ann Surg Oncol. 1996 Sep;3(5):419-20 [8876881.001]
  • [Cites] Oncology (Williston Park). 1996 Nov;10(11):1701-8, 1713-4; discussion 1714-18 [8953589.001]
  • [Cites] Lancet. 1996 Dec 14;348(9042):1605-10 [8961989.001]
  • [Cites] Dis Colon Rectum. 1997 Feb;40(2):131-9 [9075745.001]
  • [Cites] Radiographics. 1997 May-Jun;17(3):609-26 [9153700.001]
  • [Cites] Radiology. 1997 Aug;204(2):533-8 [9240549.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Feb 1;40(3):569-74 [9486606.001]
  • [Cites] Ann Surg Oncol. 1998 Mar;5(2):113-8 [9527263.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 15;40(5):1067-75 [9539561.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):51-7 [9747819.001]
  • [Cites] Ann Surg. 1999 Apr;229(4):493-7 [10203081.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1027-38 [10421535.001]
  • (PMID = 16722598.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC1459184
  • [General-notes] NLM/ Original DateCompleted: 20060619
  •  go-up   go-down


37. Attia S, Traynor AM, Kim K, Merchant JJ, Hoang T, Ahuja HG, Beatty PA, Hansen RM, Masters GA, Oettel KR, Shapiro GR, Larson MM, Larson ML, Schiller JH: Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study. J Thorac Oncol; 2008 Sep;3(9):1018-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study.
  • INTRODUCTION: Exisulind is an apoptotic agent with preclinical activity in non-small cell lung cancer (NSCLC).
  • METHODS: Chemotherapy-naive patients >/=70-years-old with stage IIIB-IV NSCLC and a performance status (PS) </=2 were eligible.
  • Primary endpoints were the maximum tolerated dose (phase I) and time-to-progression (phase II) of oral exisulind with 25 mg/m/wk of intravenous vinorelbine on a 28-day cycle.
  • Thirty phase II patients (median PS 1; median age 78 years) were enrolled.
  • Phase II median time-to-progression was 4.7 months (95% CI: 3.1-9.3 months) and median OS was 9.6 months (95% CI: 6.6-19.1 months).

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6178-84 [10626810.001]
  • [Cites] Oncologist. 2007 Dec;12(12):1416-24 [18165618.001]
  • [Cites] Cancer. 2000 Jun 15;88(12):2677-85 [10870049.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3338-42 [10910034.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2690-5 [10914711.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4136-41 [11051267.001]
  • [Cites] Oncologist. 2001;6 Suppl 1:4-7 [11181997.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):494-502 [11786579.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):904-12 [11895925.001]
  • [Cites] Mol Cancer Ther. 2003 May;2(5):479-88 [12748310.001]
  • [Cites] Eur J Cancer. 2003 Nov;39(16):2264-72 [14556916.001]
  • [Cites] J Am Geriatr Soc. 1968 May;16(5):622-6 [5646906.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Clin Pharmacol Ther. 1985 Aug;38(2):228-34 [4017423.001]
  • [Cites] Clin Pharmacol Ther. 1985 Oct;38(4):387-93 [4042521.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] J Pharm Biomed Anal. 1995 Dec;14(1-2):213-20 [8833984.001]
  • [Cites] Eur J Cancer. 1997 Feb;33(2):301-3 [9135505.001]
  • [Cites] Eur J Cancer. 1997 Mar;33(3):392-7 [9155522.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2452-9 [9192825.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1250-9 [9849488.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2831-9 [15837997.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):3125-37 [15860872.001]
  • [Cites] Clin Lung Cancer. 2005 May;6(6):361-6 [15943897.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5892-9 [16043829.001]
  • [Cites] Cancer. 2005 Nov 1;104(9):1998-2005 [16206252.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3187-205 [16682719.001]
  • [Cites] Eur J Cancer. 2006 Oct;42(15):2433-53 [16750358.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cancer Control. 2007 Jan;14(1):32-43 [17242669.001]
  • [Cites] J Thorac Oncol. 2006 Mar;1(3):218-25 [17409860.001]
  • [Cites] J Thorac Oncol. 2006 Sep;1(7):673-8 [17409935.001]
  • [Cites] J Clin Oncol. 2007 May 10;25(14):1824-31 [17488980.001]
  • [Cites] J Thorac Oncol. 2007 Oct;2(10):933-8 [17909356.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5381-9 [18048819.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):78-89 [10656435.001]
  • (PMID = 18758305.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA014520-33; United States / NCI NIH HHS / CA / T32 CA009614-18; United States / NCI NIH HHS / CA / CA062491-14; United States / NCI NIH HHS / CA / CA014520-34S2; United States / NCI NIH HHS / CA / T32 CA009614-14; United States / NCI NIH HHS / CA / T32 CA009614-11; United States / NCI NIH HHS / CA / T32 CA009614-10; United States / NCI NIH HHS / CA / CA009614-15; United States / NCI NIH HHS / CA / T32 CA009614-15; United States / NCI NIH HHS / CA / CA087718-08; United States / NCI NIH HHS / CA / CA009614-16A1; United States / NCI NIH HHS / CA / CA014520-31S1; United States / NCI NIH HHS / CA / P30 CA014520-33S1; United States / NCI NIH HHS / CA / P30 CA014520-32; None / None / / P30 CA014520-33; United States / NCI NIH HHS / CA / T32 CA009614-16A1; United States / NCI NIH HHS / CA / P30 CA014520-32S1; United States / NCI NIH HHS / CA / K12 CA087718-07; United States / NCI NIH HHS / CA / P30 CA014520-34; United States / NCI NIH HHS / CA / U01 CA062491-11; United States / NCI NIH HHS / CA / P30 CA014520; None / None / / P30 CA014520-32; United States / NCI NIH HHS / CA / CA014520-34S1; United States / NCI NIH HHS / CA / U01 CA062491-10; United States / NCI NIH HHS / CA / CA062491-11; United States / NCI NIH HHS / CA / CA062491-13; United States / NCI NIH HHS / CA / P30 CA014520-33S2; United States / NCI NIH HHS / CA / CA009614-14; United States / NCI NIH HHS / CA / P30 CA014520-31; United States / NCI NIH HHS / CA / U01 CA062491; United States / NCI NIH HHS / CA / K12 CA087718; United States / NCI NIH HHS / CA / CA009614-12; None / None / / P30 CA014520-30; United States / NCI NIH HHS / CA / CA014520-33S2; United States / NCI NIH HHS / CA / U01 CA062491-13; United States / NCI NIH HHS / CA / CA009614-17; United States / NCI NIH HHS / CA / P30 CA014520-31S1; United States / NCI NIH HHS / CA / CA014520-32S1; United States / NCI NIH HHS / CA / P30 CA14520; United States / NCI NIH HHS / CA / T32 CA009614; United States / NCI NIH HHS / CA / CA009614-11; None / None / / P30 CA014520-34; United States / NCI NIH HHS / CA / P30 CA014520-30; United States / NCI NIH HHS / CA / T32 CA009614-13; None / None / / P30 CA014520-31; United States / NCI NIH HHS / CA / CA009614-18; United States / NCI NIH HHS / CA / CA062491-12; United States / NCI NIH HHS / CA / P30 CA014520-34S1; United States / NCI NIH HHS / CA / CA009614-13; United States / NCI NIH HHS / CA / T32 CA009614-17; United States / NCI NIH HHS / CA / U01 CA062491-12; United States / NCI NIH HHS / CA / T32 CA009614-12; United States / NCI NIH HHS / CA / U01 CA062491-14; United States / NCI NIH HHS / CA / P30 CA014520-34S2; United States / NCI NIH HHS / CA / K12 CA087718-08; United States / NCI NIH HHS / CA / CA009614-10; United States / NCI NIH HHS / CA / CA014520-33S1
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 184SNS8VUH / Sulindac; 5V9KLZ54CY / Vinblastine; K619IIG2R9 / sulindac sulfone; Q6C979R91Y / vinorelbine
  • [Other-IDs] NLM/ NIHMS52764; NLM/ PMC2562273
  •  go-up   go-down


38. Yoo JH, Hasegawa H, Ishii Y, Nishibori H, Watanabe M, Kitajima M: Long-term outcome of per anum intersphincteric rectal dissection with direct coloanal anastomosis for lower rectal cancer. Colorectal Dis; 2005 Sep;7(5):434-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of per anum intersphincteric rectal dissection with direct coloanal anastomosis for lower rectal cancer.
  • With direct coloanal anastomosis for cases of lower rectal cancer in which the distal surgical margin is difficult to secure by the double stapling technique.
  • Of these, two patients (one stage 0 and one stage IV) were excluded from the analysis of oncological outcome.
  • There was an association between distant metastasis and TNM or pT stage.
  • The overall survival rates for stage I, II and III were 85%, 80% and 89%, respectively.
  • CONCLUSION: The surgical indications of this operation should be limited to patients with T1 rectal cancer or tumours less than 3 cm.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Fecal Incontinence / epidemiology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Proctocolectomy, Restorative. Rectum / surgery. Surveys and Questionnaires. Survival Rate

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16108877.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


39. Schöllnberger H, Manuguerra M, Bijwaard H, Boshuizen H, Altenburg HP, Rispens SM, Brugmans MJ, Vineis P: Analysis of epidemiological cohort data on smoking effects and lung cancer with a multi-stage cancer model. Carcinogenesis; 2006 Jul;27(7):1432-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of epidemiological cohort data on smoking effects and lung cancer with a multi-stage cancer model.
  • A stochastic two-stage cancer model is used to analyse the relation between lung cancer and cigarette smoking.
  • These include the data of a large prospective collaborative project carried out in 10 different European countries, the European Prospective Investigation into Cancer and Nutrition (EPIC).
  • The model is also tested on other published data from CPS-II (Cancer Prevention Study II) of the American Cancer Society and the British doctors' study.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • MedlinePlus Health Information. consumer health - Smoking and Youth.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Free Radic Biol Med. 2003 Feb 1;34(3):345-55 [12543250.001]
  • [Cites] Pathol Biol (Paris). 1997 Dec;45(10):852-63 [9769949.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3 [5279523.001]
  • [Cites] Br J Cancer. 1957 Jun;11(2):161-9 [13460138.001]
  • [Cites] J Radiol Prot. 2002 Sep;22(3A):A43-9 [12400946.001]
  • [Cites] J Pathol. 1999 Jan;187(1):8-18 [10341702.001]
  • [Cites] J Natl Cancer Inst. 1989 Mar 15;81(6):415-20 [2783979.001]
  • [Cites] Science. 1996 Oct 18;274(5286):430-2 [8832894.001]
  • [Cites] Risk Anal. 1993 Jun;13(3):273-9 [8341806.001]
  • [Cites] Int J Radiat Biol. 2002 Jan;78(1):49-68 [11747553.001]
  • [Cites] Int J Cancer. 2001 Mar 15;91(6):876-87 [11275995.001]
  • [Cites] Epidemiology. 1993 May;4(3):204-17 [8512985.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 17;85(6):457-64 [8445673.001]
  • [Cites] Bull Math Biol. 2001 Sep;63(5):865-83 [11565407.001]
  • [Cites] Carcinogenesis. 2001 Mar;22(3):367-74 [11238174.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Jun;280(6):L1189-95 [11350797.001]
  • [Cites] Trends Pharmacol Sci. 2003 Feb;24(2):71-6 [12559770.001]
  • [Cites] Nonlinearity Biol Toxicol Med. 2004 Oct;2(4):317-52 [19330150.001]
  • [Cites] Int J Radiat Biol. 2002 Dec;78(12):1159-73 [12556343.001]
  • [Cites] Mutat Res. 2004 Nov;567(2-3):447-74 [15572290.001]
  • [Cites] Br J Cancer. 1954 Mar;8(1):1-12 [13172380.001]
  • [Cites] Radiat Environ Biophys. 2005 Oct;44(2):145-8 [16187080.001]
  • [Cites] Radiat Environ Biophys. 1996 May;35(2):127-9 [8792461.001]
  • [Cites] Epidemiology. 1994 Jan;5(1):27-34 [8117778.001]
  • [Cites] Nat Genet. 2003 Jul;34(3):255-9 [12833049.001]
  • [Cites] Br J Cancer. 1953 Mar;7(1):68-72 [13051507.001]
  • [Cites] Int J Epidemiol. 1997;26 Suppl 1:S6-14 [9126529.001]
  • [Cites] J Radiol Prot. 2002 Sep;22(3A):A75-9 [12400952.001]
  • [Cites] Stat Med. 2002 Oct 30;21(20):3055-70 [12369081.001]
  • [Cites] Oncogene. 2002 Oct 21;21(48):7392-411 [12379881.001]
  • [Cites] Radiat Environ Biophys. 1999 May;38(1):57-71 [10384956.001]
  • [Cites] JAMA. 2005 Mar 9;293(10):1212-22 [15755944.001]
  • [Cites] Pathol Oncol Res. 2001;7(1):6-13 [11349214.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Aug;281(2):L509-16 [11435227.001]
  • [Cites] Radiat Environ Biophys. 1997 Feb;36(1):45-58 [9128898.001]
  • [Cites] Biometrics. 1995 Dec;51(4):1278-91 [8589222.001]
  • [Cites] Int J Radiat Biol. 1990 Feb;57(2):407-23 [1968504.001]
  • [Cites] Pathol Biol (Paris). 1997 Dec;45(10):833-44 [9769947.001]
  • [Cites] BMJ. 2004 Jun 26;328(7455):1519 [15213107.001]
  • [Cites] Risk Anal. 1990 Jun;10(2):323-41 [2195604.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):240-51 [12619109.001]
  • [Cites] Radiat Res. 2003 Apr;159(4):511-20 [12643796.001]
  • [Cites] Oncogene. 2002 Oct 21;21(48):7435-51 [12379884.001]
  • [Cites] Br Med J. 1964 May 30;1(5395):1399-410 [14135164.001]
  • [Cites] Exp Pathol. 1990;38(1):19-29 [2328782.001]
  • [Cites] Thorax. 1998 Nov;53(11):979-83 [10193399.001]
  • [Cites] Radiat Environ Biophys. 2004 Sep;43(3):153-63 [15316819.001]
  • [Cites] Br J Cancer. 1953 Dec;7(4):407-17 [13126381.001]
  • [Cites] J Natl Cancer Inst. 1971 Jul;47(1):235-40 [5570117.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 Nov;29(5):562-70 [12748058.001]
  • [Cites] Int J Cancer. 2004 Jan 10;108(2):269-76 [14639614.001]
  • [Cites] J Epidemiol Community Health. 1978 Dec;32(4):303-13 [744822.001]
  • [Cites] Radiat Environ Biophys. 1977 Oct 12;14(3):195-211 [928628.001]
  • [Cites] Radiat Res. 1999 Oct;152(4):339-51 [10477911.001]
  • [Cites] Risk Anal. 1997 Jun;17(3):391-9 [9232020.001]
  • [Cites] J Natl Cancer Inst. 1978 Jul;61(1):49-52 [276637.001]
  • [Cites] Radiat Res. 2001 Jul;156(1):78-94 [11418076.001]
  • [Cites] Radiat Res. 2001 Nov;156(5 Pt 2):678-81 [11604092.001]
  • [Cites] J Natl Cancer Inst. 1981 Jun;66(6):1037-52 [6941039.001]
  • [Cites] Mutat Res. 1999 Jul 16;428(1-2):23-32 [10517975.001]
  • (PMID = 16410261.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / P 18055
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3085129; NLM/ UKMS29515
  •  go-up   go-down


40. Zhou HT, Zhou ZX, Zhang HZ, Bi JJ, Zhao P: Wide local excision could be considered as the initial treatment of primary anorectal malignant melanoma. Chin Med J (Engl); 2010 Mar 5;123(5):585-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Rectal bleeding and anal mass were found to be common symptoms of anorectal malignant melanoma.
  • The 3-year survival rates of stage I and II patients were 63.0% and 16.7% respectively (P = 0.000), and the 5-year survival rates were 33.3% and 11.1% (P = 0.001), which both had significant statistic differences.
  • [MeSH-major] Anus Neoplasms / surgery. Melanoma / surgery

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20367986.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


41. Law WL, Ho JW, Chan R, Au G, Chu KW: Outcome of anterior resection for stage II rectal cancer without radiation: the role of adjuvant chemotherapy. Dis Colon Rectum; 2005 Feb;48(2):218-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of anterior resection for stage II rectal cancer without radiation: the role of adjuvant chemotherapy.
  • BACKGROUND: This study aimed to evaluate the oncological outcome of patients who had Stage II rectal cancer and underwent curative nonsphincter-ablation surgery without adjuvant radiation.
  • PATIENTS AND METHODS: During the study period from August 1993 to December 2002, 224 patients (141 men) with Stage II cancer underwent curative anterior resection or Hartmann's procedure without adjuvant radiation.
  • RESULTS: The median age of the patients was 69 (range, 27-89) years and the median level of the tumor from the anal verge was 8 (range, 3-20) cm.
  • The overall and cancer-specific survival rates of the patients were 71.1 percent and 81.1 percent, respectively.
  • On multivariate analysis, only adjuvant chemotherapy (P = 0.024; hazard ratio = 6.04; 95 percent confidence interval, 1.27-28.74) and the absence of lymphovascular invasion (P = 0.002; hazard ratio = 3.77; 95 percent confidence interval, 1.63-8.77) were independent factors associated with significantly better cancer-specific survival.
  • CONCLUSION: A low local recurrence rate can be achieved in patients with Stage II rectal cancer treated with nonsphincter-ablation surgery without adjuvant radiation.
  • Further study is warranted to define the role of adjuvant chemotherapy in patients with rectal cancer.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dis Colon Rectum. 2006 Jan;49(1):143; author reply 143-4 [16270164.001]
  • (PMID = 15711860.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Kidd EA, Dehdashti F, Siegel BA, Grigsby PW: Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis. Radiother Oncol; 2010 Jun;95(3):288-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis.
  • PURPOSE: To evaluate anal cancer uptake of F-18 fluorodeoxyglucose (FDG) measured as the maximum standardized uptake value (SUV(max)) by positron emission tomography (PET) and its correlation with prognostic factors.
  • PATIENTS AND METHODS: The study population consisted of 77 patients with stages 0-IIIB anal cancer who underwent pre-treatment FDG-PET.
  • The stage distribution included: 2 stage 0, 7 stage I, 49 stage II, 10 stage IIIA, 9 stage IIIB.
  • Patients with high anal tumor SUV(max) at diagnosis were at an increased risk of persistent or recurrent disease on post-therapy FDG-PET performed less than 4months after completing therapy (p=0.0402).
  • CONCLUSIONS: SUV(max) is a valuable biomarker of anal cancer prognosis, predicting increased risk of lymph node metastasis and worse disease-free survival.
  • [MeSH-major] Anus Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18 / pharmacokinetics. Positron-Emission Tomography. Radiopharmaceuticals / pharmacokinetics

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20231040.001).
  • [ISSN] 1879-0887
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


43. Tajima Y, Ishibashi K, Gonda T, Miyazaki T, Nakada H, Takahashi T, Ishida H: [Squamous cell carcinoma of the anal canal showing complete response following chemoradiotherapy--a case report]. Gan To Kagaku Ryoho; 2007 Nov;34(12):2050-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Squamous cell carcinoma of the anal canal showing complete response following chemoradiotherapy--a case report].
  • We report a case of squamous cell carcinoma of the anal canal which showed complete response following chemoradiotherapy.
  • A 54-year-old woman was diagnosed as having squamous cell carcinoma of the anal canal (T2N0M0 stage II).
  • This case suggests that we should take measures to prevent distant metastases in the treatment of squamous cell carcinoma of the anal canal.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219895.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


44. Thall PF: A review of phase 2-3 clinical trial designs. Lifetime Data Anal; 2008 Mar;14(1):37-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is followed by descriptions of some particular phase 2-3 designs that have been proposed, including two-stage designs to evaluate one experimental treatment, a design that accommodates both frontline and salvage therapy in oncology, two-stage select-and-test designs that evaluate several experimental treatments, dose-ranging designs, and a seamless phase 2-3 design based on both early response-toxicity outcomes and later event times.
  • [MeSH-major] Clinical Trials, Phase II as Topic / methods. Clinical Trials, Phase III as Topic / methods. Research Design

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7199-206 [16192604.001]
  • [Cites] Stat Med. 1995 Feb 28;14(4):357-79 [7746977.001]
  • [Cites] Stat Med. 2005 May 30;24(10):1455-81 [15586395.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] Stat Med. 1986 Sep-Oct;5(5):459-64 [3787000.001]
  • [Cites] Stat Med. 2007 Nov 20;26(26):4687-702 [17427204.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Stat Med. 2000 Apr 30;19(8):1011-28 [10790677.001]
  • [Cites] Cancer Treat Rep. 1985 Dec;69(12):1375-81 [4075313.001]
  • [Cites] Clin Trials. 2004 Feb;1(1):9-20 [16281458.001]
  • [Cites] Biometrics. 1989 Jun;45(2):537-47 [2765637.001]
  • [Cites] Stat Med. 1994 Mar 15-Apr 15;13(5-7):417-29 [8023026.001]
  • [Cites] Control Clin Trials. 1988 Jun;9(2):107-18 [3396362.001]
  • [Cites] Blood. 2003 Jul 15;102(2):442-8 [12560224.001]
  • [Cites] Biometrics. 2002 Dec;58(4):823-31 [12495136.001]
  • [Cites] Biometrics. 1995 Dec;51(4):1372-83 [8589229.001]
  • [Cites] Biometrics. 1987 Dec;43(4):865-74 [3427171.001]
  • [Cites] Biometrics. 2004 Sep;60(3):684-93 [15339291.001]
  • [Cites] Biometrics. 1994 Jun;50(2):337-49 [7980801.001]
  • [Cites] Clin Trials. 2007;4(2):113-24 [17456511.001]
  • [Cites] Cancer Treat Rep. 1985 Oct;69(10):1147-54 [4042093.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 18;84(6):407-14 [1531682.001]
  • [Cites] J Chronic Dis. 1961 Apr;13:346-53 [13704181.001]
  • [Cites] Stat Med. 1990 Mar;9(3):215-28 [2188324.001]
  • [Cites] Stat Med. 1988 May;7(5):571-9 [3387716.001]
  • (PMID = 17763973.001).
  • [ISSN] 1380-7870
  • [Journal-full-title] Lifetime data analysis
  • [ISO-abbreviation] Lifetime Data Anal
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 83932
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


45. Chung FY, Huang MY, Yeh CS, Chang HJ, Cheng TL, Yen LC, Wang JY, Lin SR: GLUT1 gene is a potential hypoxic marker in colorectal cancer patients. BMC Cancer; 2009;9:241
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GLUT1 gene is a potential hypoxic marker in colorectal cancer patients.
  • This study investigated molecules synthesized in colorectal cancer cells during hypoxia to explore the possibility of developing molecular probes capable of detecting cell death and/or the efficiency of radiotherapy and chemotherapy.
  • METHODS: At first, we incubated two human colorectal adenocarcinoma cell lines SW480 (UICC stage II) and SW620 (UICC stage III) cells in hypoxic (< or =2% O2, 93% N2, and 5% CO2) and normoxic conditions (20% O2, 75% N2, and 5% CO2) for 24 h and 48 h.
  • Ten cancerous tissues collected from human colorectal cancer patients were examined.
  • The elevated ratio of GLUT1 was higher in stage III and IV CRC tissue specimens than in the stage I and II (2.97-4.73 versus 1.44-2.11).
  • GLUT1 mRNA was also increased in the peripheral blood of stage II and III CRC patients as compared to stage I patients, suggesting that GLUT1 may serve as a hypoxic indicator in CRC patients.
  • CONCLUSION: In conclusion, this study demonstrated that GLUT1 has the potential to be employed as a molecular marker to indicate the degree of hypoxia experienced by tumors circulating in the blood of cancer patients.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Abdom Imaging. 2008 May-Jun;33(3):270-7 [17610107.001]
  • [Cites] Eur J Cancer. 2008 Mar;44(5):692-8 [18314327.001]
  • [Cites] Mol Cell Endocrinol. 2008 Sep 10;291(1-2):57-62 [18571834.001]
  • [Cites] Colorectal Dis. 2009 Mar;11(3):276-81 [18513194.001]
  • [Cites] CA Cancer J Clin. 2002 Nov-Dec;52(6):326-41 [12469762.001]
  • [Cites] Hepatogastroenterology. 2000 Jan-Feb;47(31):57-70 [10690586.001]
  • [Cites] J Exp Biol. 2000 Apr;203(Pt 8):1253-63 [10729275.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] Cancer Lett. 2000 Jun 30;154(2):175-82 [10806305.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4693-6 [10987269.001]
  • [Cites] Prev Med. 2000 Oct;31(4):410-6 [11006067.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14608-13 [11121063.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] Urology. 2002 Oct;60(4):634-9 [12385924.001]
  • [Cites] Eur J Surg Oncol. 2004 Jun;30(5):465-8 [15135470.001]
  • [Cites] J Natl Cancer Inst. 1967 Jun;38(6):839-63 [4381692.001]
  • [Cites] Cancer Res. 1972 Oct;32(10):2007-16 [4343003.001]
  • [Cites] Prog Exp Tumor Res. 1978;22:190-274 [149996.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Aug;83(16):5784-8 [3016720.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Diabetes. 1988 May;37(5):657-61 [2834252.001]
  • [Cites] J Biol Chem. 1989 Nov 15;264(32):18884-9 [2553725.001]
  • [Cites] J Biol Chem. 1992 Jul 25;267(21):14523-6 [1634504.001]
  • [Cites] Radiother Oncol. 1993 Jan;26(1):45-50 [8438086.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):401-9 [7688183.001]
  • [Cites] Eur J Surg Oncol. 1995 Jun;21(3):269-75 [7781795.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):941-3 [8640781.001]
  • [Cites] Stem Cells. 1996 Jan;14(1):10-5 [8820945.001]
  • [Cites] NMR Biomed. 1996 Aug;9(5):185-94 [9067999.001]
  • [Cites] Gastroenterology. 1997 Apr;112(4):1103-13 [9097992.001]
  • [Cites] Genes Dev. 1998 Jan 15;12(2):149-62 [9436976.001]
  • [Cites] Trends Biochem Sci. 1999 Feb;24(2):68-72 [10098401.001]
  • [Cites] Oncologia. 1956;9(2):75-83 [13335077.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8554-60 [15623639.001]
  • [Cites] DNA Cell Biol. 2005 Feb;24(2):126-32 [15699632.001]
  • [Cites] Cancer Lett. 2005 Nov 8;229(1):115-22 [16157223.001]
  • [Cites] Int J Oncol. 2006 Feb;28(2):411-20 [16391796.001]
  • [Cites] Cytometry B Clin Cytom. 2006 Mar;70(2):45-55 [16456867.001]
  • [Cites] Int J Mol Med. 2006 May;17(5):737-47 [16596255.001]
  • [Cites] Cancer Lett. 2006 Aug 28;240(2):279-88 [16289546.001]
  • [Cites] Int J Radiat Biol. 2006 Oct;82(10):699-757 [17118889.001]
  • [Cites] Strahlenther Onkol. 2007 May;183(5):265-70 [17497098.001]
  • [Cites] Antioxid Redox Signal. 2007 Aug;9(8):1221-35 [17536958.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):167-75 [17707270.001]
  • [Cites] J Natl Cancer Inst. 2007 Oct 3;99(19):1441-54 [17895480.001]
  • [Cites] Jpn J Clin Oncol. 2007 Dec;37(12):955-60 [18211986.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):348-52 [17962202.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2007 Sep;29(9):697-700 [18246802.001]
  • [Cites] Adv Exp Med Biol. 2008;614:127-36 [18290322.001]
  • [Cites] Gynecol Oncol. 2008 Mar;108(3):603-8 [18191183.001]
  • [Cites] BMC Cancer. 2008;8:194 [18616803.001]
  • (PMID = 19619276.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ARNT protein, human; 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / RNA, Messenger; 138391-32-9 / Aryl Hydrocarbon Receptor Nuclear Translocator
  • [Other-IDs] NLM/ PMC3087329
  •  go-up   go-down


46. Prete F, Prete FP, Nitti P, De Luca R, Vincenti L: [Evolution of surgery for cancer of the anorectal junction]. Chir Ital; 2007 Nov-Dec;59(6):763-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evolution of surgery for cancer of the anorectal junction].
  • [Transliterated title] Evoluzione chirurgica per i tumori del giunto ano-rettale.
  • Certain aspects of the epidemiology, classification and therapy of adenocarcinoma of the anorectal junction (< 5 cm from the anal verge) are not well standardised to date.
  • Intersphincteric resections were performed in 51 males and 33 females, mean age 62, with the following clinical stages: 28 stage 1, 55 stages II and III, 1 stage IV; radiotherapy was administered preoperatively to 27 patients and postoperatively to 18.
  • Assessment of anal sphincter function recovery one year after restoration of bowel continuity showed good continence in 76% of the patients; 2 patients have a permanent ostomy.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18360980.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


47. Damestoy A, Perrard MH, Vigier M, Sabido O, Durand P: Transforming growth factor beta-1 decreases the yield of the second meiotic division of rat pachytene spermatocytes in vitro. Reprod Biol Endocrinol; 2005;3:22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Higher numbers of metaphase II were present and their number was enhanced by TGF beta-1 treatment.
  • CONCLUSION: These results indicate that TGF beta-1 did not change greatly, if any, the yield of the first meiotic division but likely enhanced a bottleneck at the level of metaphase II.
  • [MeSH-major] Pachytene Stage / physiology. Spermatocytes / cytology. Transforming Growth Factor beta / physiology

  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chromosoma. 1999 Dec;108(7):412-25 [10654080.001]
  • [Cites] Gene. 2000 Apr 18;247(1-2):1-15 [10773440.001]
  • [Cites] Endocrinology. 2000 May;141(5):1795-803 [10803590.001]
  • [Cites] Chromosoma. 2000;109(5):308-17 [11007489.001]
  • [Cites] Exp Cell Res. 2000 Oct 10;260(1):85-95 [11010813.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Sep 29;238(3):905-9 [9325190.001]
  • [Cites] Annu Rev Cell Dev Biol. 1997;13:261-91 [9442875.001]
  • [Cites] Endocrinology. 1998 Feb;139(2):733-40 [9449647.001]
  • [Cites] Mol Reprod Dev. 1998 Sep;51(1):22-35 [9712314.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13612-7 [9811848.001]
  • [Cites] Nat Genet. 1998 Dec;20(4):377-80 [9843212.001]
  • [Cites] Histochem Cell Biol. 1998 Dec;110(6):613-8 [9860260.001]
  • [Cites] Oncogene. 1999 Jan 7;18(1):269-75 [9926943.001]
  • [Cites] Biol Reprod. 1999 Jun;60(6):1304-13 [10330085.001]
  • [Cites] J Mol Endocrinol. 2004 Dec;33(3):729-42 [15591031.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14961-6 [10611320.001]
  • [Cites] Eur J Cell Biol. 2000 Nov;79(11):816-23 [11139145.001]
  • [Cites] Endocrinology. 2001 May;142(5):1865-77 [11316752.001]
  • [Cites] Biol Reprod. 2001 Sep;65(3):873-8 [11514353.001]
  • [Cites] Hum Reprod. 2002 Jan;17(1):161-72 [11756382.001]
  • [Cites] Recent Prog Horm Res. 2002;57:149-79 [12017541.001]
  • [Cites] Blood. 2002 Jul 15;100(2):560-8 [12091349.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13498-503 [12370412.001]
  • [Cites] J Androl. 2003 Mar-Apr;24(2):192-200 [12634305.001]
  • [Cites] Asian J Androl. 2003 Mar;5(1):51-5 [12647004.001]
  • [Cites] Mol Reprod Dev. 2003 May;65(1):86-95 [12658637.001]
  • [Cites] Int J Androl. 2003 Jun;26(3):147-60 [12755993.001]
  • [Cites] Mol Cell Biol. 2003 Jun;23(12):4371-85 [12773577.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3340-6 [12810668.001]
  • [Cites] Biol Reprod. 2003 Jul;69(1):169-76 [12620938.001]
  • [Cites] Biol Reprod. 2003 Aug;69(2):592-601 [12700195.001]
  • [Cites] Nat Genet. 2003 Sep;35(1):25-31 [12923533.001]
  • [Cites] Curr Biol. 2003 Oct 14;13(20):1775-85 [14561402.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13692-7 [14585929.001]
  • [Cites] Development. 2004 Jan;131(2):459-67 [14701682.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1327-32 [14745012.001]
  • [Cites] Biol Reprod. 2004 Apr;70(4):1147-52 [14695906.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 4;101(18):6876-81 [15107499.001]
  • [Cites] Reprod Biol Endocrinol. 2003 Feb 5;1:3 [12646048.001]
  • [Cites] Endocrinology. 1983 Mar;112(3):1150-2 [6822207.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] J Cell Physiol. 1989 Jan;138(1):79-86 [2910889.001]
  • [Cites] Nature. 1992 Oct 22;359(6397):693-9 [1436033.001]
  • [Cites] Biol Reprod. 1993 Jan;48(1):40-5 [8418916.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):770-4 [8421714.001]
  • [Cites] Mol Endocrinol. 1993 Jan;7(1):67-76 [8446109.001]
  • [Cites] Endocrinology. 1993 Oct;133(4):1664-8 [8404607.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10315-9 [7694291.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):4971-4 [7890601.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5545-9 [7777546.001]
  • [Cites] Nat Genet. 1995 Dec;11(4):415-21 [7493022.001]
  • [Cites] Dev Biol. 1996 Oct 10;179(1):297-302 [8873772.001]
  • [Cites] Biol Reprod. 1997 Feb;56(2):357-67 [9116134.001]
  • [Cites] Nat Genet. 1997 Feb;15(2):201-4 [9020850.001]
  • [Cites] Mol Reprod Dev. 1997 Jul;47(3):240-7 [9170103.001]
  • [Cites] Biol Reprod. 1997 Jul;57(1):68-76 [9209082.001]
  • [Cites] Development. 1997 Jul;124(13):2659-70 [9217007.001]
  • (PMID = 15941479.001).
  • [ISSN] 1477-7827
  • [Journal-full-title] Reproductive biology and endocrinology : RB&E
  • [ISO-abbreviation] Reprod. Biol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Tgfb1 protein, rat; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; G34N38R2N1 / Bromodeoxyuridine
  • [Other-IDs] NLM/ PMC1156949
  •  go-up   go-down


48. Hattis D, Goble R, Chu M: Age-related differences in susceptibility to carcinogenesis. II. Approaches for application and uncertainty analyses for individual genetically acting carcinogens. Environ Health Perspect; 2005 Apr;113(4):509-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age-related differences in susceptibility to carcinogenesis. II. Approaches for application and uncertainty analyses for individual genetically acting carcinogens.
  • Here we draw implications for assessing human risks for full lifetime exposures, taking into account three types of uncertainties in making projections from the rodent data: uncertainty in the central estimates of the life-stage-specific sensitivity factors estimated earlier, uncertainty from chemical-to-chemical differences in life-stage-specific sensitivities for carcinogenesis, and uncertainty in the mapping of rodent life stages to human ages/exposure periods.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncol Res. 1999;11(4):169-78 [10566615.001]
  • [Cites] Drug Metab Rev. 1998 Aug;30(3):441-98 [9710703.001]
  • [Cites] Drug Metab Dispos. 2001 Jan;29(1):8-16 [11124223.001]
  • [Cites] Contemp Top Lab Anim Sci. 2002 Sep;41(5):21-6 [12213043.001]
  • [Cites] Risk Anal. 2003 Feb;23(1):19-34 [12635720.001]
  • [Cites] Radiat Res. 2003 Oct;160(4):381-407 [12968934.001]
  • [Cites] Toxicol Appl Pharmacol. 2003 Dec 1;193(2):293-302 [14644629.001]
  • [Cites] Environ Health Perspect. 2004 Aug;112(11):1152-8 [15289159.001]
  • [Cites] Int J Cancer. 1969 Jul 15;4(4):480-6 [5346885.001]
  • [Cites] Br J Cancer. 1976 May;33(5):521-34 [179560.001]
  • [Cites] Am J Epidemiol. 1977 Nov;106(5):418-32 [920729.001]
  • [Cites] J Natl Cancer Inst. 1980 Apr;64(4):977-89 [6929006.001]
  • [Cites] J Natl Cancer Inst. 1987 Mar;78(3):413-8 [3469454.001]
  • [Cites] Risk Anal. 1986 Jun;6(2):155-66 [3615985.001]
  • [Cites] Cancer Res. 1992 Apr 1;52(7):1804-9 [1372530.001]
  • [Cites] Biochem Pharmacol. 1994 Mar 29;47(7):1221-9 [8161351.001]
  • [Cites] Int J Biochem Cell Biol. 1995 Jan;27(1):9-20 [7757886.001]
  • [Cites] Radiat Res. 1999 Dec;152(6):642-54 [10581535.001]
  • (PMID = 15811844.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Mutagens
  • [Other-IDs] NLM/ PMC1278495
  •  go-up   go-down


49. Sill MW, Sampson AR: Drop-the-Losers Design: Binomial Case. Comput Stat Data Anal; 2009 Jan 1;53(3):586-595
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Drop-the-losers designs were introduced for normal distributions as a method of combining phase II and III clinical trials together under a single protocol with the purpose of more rapidly evaluating drugs by eliminating as much as possible the delays that typically occur between the two phases of clinical development.
  • In the design, the sponsor would administer k treatments along with a control in the first stage.
  • During a brief interim period, efficacy data would be used to select the best treatment (with a rule to deal with ties) for further evaluation against the control in a second stage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20047003.001).
  • [ISSN] 0167-9473
  • [Journal-full-title] Computational statistics & data analysis
  • [ISO-abbreviation] Comput Stat Data Anal
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / MH045156-189002; United States / NCI NIH HHS / CA / U10 CA037517
  • [Publication-type] JOURNAL ARTICLE
  • [Publication-country] Netherlands
  •  go-up   go-down


50. Nakagawa S, Amano M, Yamashita S, Nishikawa Y, Higaki N, Hayashida H, Niinobu T, Yoshioka Y, Sakon M: [A case of effective chemoradiation therapy against anal fistula carcinoma recurred 10 years after surgery]. Gan To Kagaku Ryoho; 2006 Nov;33(12):1977-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of effective chemoradiation therapy against anal fistula carcinoma recurred 10 years after surgery].
  • A male in his eighties underwent abdominoperineal resection under the diagnosis of adenocarcinoma associated with anal fistula (P0, H0, n (-), A1, stage II, ly0, v0).
  • [MeSH-major] Adenocarcinoma / therapy. Anus Neoplasms / therapy. Rectal Fistula / etiology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17212165.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 1-UFT protocol
  •  go-up   go-down


51. Katsui R, Kuniyasu H, Matsuyoshi H, Fujii H, Nakajima Y, Takaki M: The plasticity of the defecation reflex pathway in the enteric nervous system of guinea pigs. J Smooth Muscle Res; 2009 Feb;45(1):1-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Appropriate rectal distension elicits rectal (R-R) reflex contractions and simultaneous internal anal sphincter (R-IAS) reflex relaxations that together comprise the defecation reflex.
  • We performed either a lower anterior resection as used for rectal cancer, without damaging the extrinsic nerves or a resection of a 2-cm segment of distal colon, 30 mm orally from the anal verge, with subsequent end-to-end one layer anastomosis of the exposed ends.
  • The 5-HT(4) receptor agonist, mosapride (0.5 and 1.0 mg/kg), significantly (P<0.01) enhanced the recovered defecation reflex at this stage.
  • Two weeks after local treatment with brain-derived neurotrophic factor (BDNF: 10(-6) g/ml) at the rectal anastomotic site, the R-IAS reflex relaxations recovered and some bundles of fine nerve fibers were able to be seen interconnecting the oral and anal ends of the myenteric plexus.
  • [MeSH-major] Anal Canal / innervation. Benzamides / pharmacology. Brain-Derived Neurotrophic Factor / pharmacology. Colon / innervation. Morpholines / pharmacology. Neuronal Plasticity. Serotonin Receptor Agonists / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19377268.001).
  • [ISSN] 1884-8796
  • [Journal-full-title] Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi
  • [ISO-abbreviation] J Smooth Muscle Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Benzamides; 0 / Brain-Derived Neurotrophic Factor; 0 / Morpholines; 0 / Serotonin Receptor Agonists; I8MFJ1C0BY / mosapride
  • [Number-of-references] 28
  •  go-up   go-down


52. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, Halverson AL: Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States. Ann Surg Oncol; 2008 Jul;15(7):1948-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States.
  • BACKGROUND: Over the past two decades, recommended treatment for squamous cell carcinoma of the anal canal has shifted from surgery to primary chemoradiation.
  • METHODS: From the National Cancer Data Base (1985-2005), 38,882 patients with anal canal cancer were identified.
  • Patients were significantly less likely to receive guideline treatment if male, older, black or Hispanic, more severe comorbidities, or Stage I (vs Stage II or III).
  • [MeSH-major] Anus Neoplasms / therapy. Neoplasms, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414951.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


53. Jurić I, Pogorelić Z, Kuzmić-Prusac I, Biocić M, Jakovljević G, Stepan J, Zupancić B, Culić S, Kruslin B: Expression and prognostic value of the Ki-67 in Wilms' tumor: experience with 48 cases. Pediatr Surg Int; 2010 May;26(5):487-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A correlation between Ki-67 and tumor stage found proliferation index significantly higher in stages I and II (P = 0.002).

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dis Child. 2006 Dec;91(12):995-9 [16857697.001]
  • [Cites] Klin Padiatr. 2008 May-Jun;220(3):183-8 [18478492.001]
  • [Cites] Neurosurgery. 2009 Sep;65(3):429-37; discussion 437 [19687686.001]
  • [Cites] Cancer. 2008 May 1;112(9):2060-70 [18361398.001]
  • [Cites] Arq Gastroenterol. 2009 Apr-Jun;46(2):116-20 [19578612.001]
  • [Cites] PLoS One. 2008 May 21;3(5):e2216 [18493303.001]
  • [Cites] Braz J Otorhinolaryngol. 2009 Jul-Aug;75(4):544-9 [19784424.001]
  • [Cites] Pediatr Hematol Oncol. 2009 Sep;26(6):407-13 [19657990.001]
  • [Cites] Br J Cancer. 2007 May 21;96(10):1504-13 [17453008.001]
  • [Cites] Dakar Med. 2005;50(2):65-8 [16295759.001]
  • [Cites] Pediatr Radiol. 2008 Jan;38(1):30-9 [18026724.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Feb;149(1):81-4 [15104289.001]
  • [Cites] Anal Cell Pathol. 1994 Aug;7(2):127-38 [7993823.001]
  • [Cites] Eur J Histochem. 2003;47(2):123-8 [12777207.001]
  • [Cites] J Cell Physiol. 2000 Mar;182(3):311-22 [10653597.001]
  • [Cites] J Neurooncol. 2002 Apr;57(2):115-21 [12125971.001]
  • [Cites] Cancer Genet Cytogenet. 2009 Aug;193(1):1-8 [19602458.001]
  • [Cites] Braz J Otorhinolaryngol. 2008 Nov-Dec;74(6):855-9 [19582341.001]
  • [Cites] Am J Clin Pathol. 1998 Oct;110(4):443-9 [9763029.001]
  • [Cites] Pediatr Blood Cancer. 2006 Sep;47(3):260-7 [16700047.001]
  • [Cites] Singapore Med J. 2009 Jul;50(7):729-33 [19644632.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):591-7 [14760081.001]
  • [Cites] Lab Invest. 1994 Jan;70(1):125-9 [7905542.001]
  • [Cites] Rev Med Chil. 2009 Jul;137(7):881-7 [19802414.001]
  • [Cites] Med Pediatr Oncol. 1998 Sep;31(3):175-6 [9722902.001]
  • [Cites] Acta Chir Belg. 2009 Oct;109(5):606-11 [19994803.001]
  • [Cites] Oncologist. 2005 Nov-Dec;10(10):815-26 [16314292.001]
  • [Cites] Rom J Morphol Embryol. 2009;50(3):413-8 [19690767.001]
  • [Cites] Pediatr Dev Pathol. 1998 May-Jun;1(3):243-8 [10463285.001]
  • [Cites] Neoplasma. 2005;52(5):420-4 [16151588.001]
  • [Cites] J Pediatr Surg. 2009 Sep;44(9):1750-3 [19735820.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):3156-7; author reply 3157-8 [15860881.001]
  • (PMID = 20306058.001).
  • [ISSN] 1437-9813
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


54. Nguyen BT, Joon DL, Khoo V, Quong G, Chao M, Wada M, Joon ML, See A, Feigen M, Rykers K, Kai C, Zupan E, Scott A: Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol; 2008 Jun;87(3):376-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the impact of FDG-PET in the management of anal cancer.
  • PURPOSE: To assess the utility of FDG-PET in anal cancer for staging and impact on radiotherapy planning (RTP), response and detection of recurrent disease.
  • METHODS AND MATERIALS: Fifty histopathological anal cancer patients were reviewed between 1996 and 2006.
  • RESULTS: The non-PET staging was Stage I(8), Stage II(18), Stage III(22), and Stage IV(2)s.
  • CONCLUSIONS: Anal cancer is FDG-PET avid.
  • PET can aid in anal cancer staging and identification of residual disease, recurrent/metastatic disease but warrants further prospective studies.
  • [MeSH-major] Anus Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18453023.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


56. de Campos-Nebel M, Larripa I, González-Cid M: Topoisomerase II-mediated DNA damage is differently repaired during the cell cycle by non-homologous end joining and homologous recombination. PLoS One; 2010;5(9)
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topoisomerase II-mediated DNA damage is differently repaired during the cell cycle by non-homologous end joining and homologous recombination.
  • Topoisomerase II (Top2) is a nuclear enzyme involved in several metabolic processes of DNA.
  • Therefore, we conclude that in human cells both NHEJ and HR are required, with cell cycle stage specificity, for the repair of Top2-mediated reversible DNA damage.
  • [MeSH-major] Cell Cycle. DNA Damage. DNA Repair. DNA Topoisomerases, Type II / metabolism. Recombination, Genetic

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2003 Apr 10;193(1):1-9 [12691817.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1377-81 [12649202.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):35897-902 [12842886.001]
  • [Cites] J Cell Sci. 2004 Mar 1;117(Pt 7):1047-54 [14996935.001]
  • [Cites] Cytometry A. 2004 Apr;58(2):99-110 [15057963.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jun 11;318(4):856-61 [15147950.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Cell. 1988 Oct 7;55(1):7-16 [3167977.001]
  • [Cites] Science. 2006 Jun 23;312(5781):1798-802 [16794079.001]
  • [Cites] Mol Cancer Ther. 2006 Jun;5(6):1405-14 [16818498.001]
  • [Cites] DNA Repair (Amst). 2006 Sep 8;5(9-10):1075-81 [16798112.001]
  • [Cites] DNA Repair (Amst). 2006 Sep 8;5(9-10):1093-108 [16857431.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):7929-41 [16923961.001]
  • [Cites] Clin Chim Acta. 2007 Apr;379(1-2):1-13 [17306783.001]
  • [Cites] J Cell Biol. 2007 Apr 23;177(2):219-29 [17438073.001]
  • [Cites] DNA Repair (Amst). 2007 Jul 1;6(7):923-35 [17363343.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):11014-9 [17578914.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7078-81 [17671173.001]
  • [Cites] J Biol Chem. 2008 Jan 4;283(1):1-5 [17999957.001]
  • [Cites] DNA Repair (Amst). 2008 Mar 1;7(3):452-63 [18206427.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):9053-8 [18574145.001]
  • [Cites] J Biol Chem. 2008 Aug 29;283(35):23711-20 [18596031.001]
  • [Cites] Cell Cycle. 2008 Sep 15;7(18):2902-6 [18769152.001]
  • [Cites] Nucleic Acids Res. 2009 Feb;37(3):738-48 [19042970.001]
  • [Cites] Apoptosis. 2010 Feb;15(2):162-72 [20041303.001]
  • [Cites] DNA Repair (Amst). 2006 May 10;5(5):575-90 [16567133.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):5778-83 [2168280.001]
  • [Cites] Cell. 1992 Sep 18;70(6):983-91 [1356077.001]
  • [Cites] J Biol Chem. 1994 Jan 14;269(2):1173-6 [8288578.001]
  • [Cites] Nucleic Acids Res. 1994 Jun 25;22(12):2274-81 [8036155.001]
  • [Cites] Annu Rev Biochem. 1996;65:635-92 [8811192.001]
  • [Cites] J Biol Chem. 1996 Nov 15;271(46):29238-44 [8910583.001]
  • [Cites] Bioessays. 1997 Feb;19(2):97-9 [9046238.001]
  • [Cites] Br J Cancer. 1997;75(9):1340-6 [9155056.001]
  • [Cites] Mol Cell Biol. 1997 Oct;17(10):6087-96 [9315668.001]
  • [Cites] Am J Hum Genet. 1997 Oct;61(4):795-800 [9382087.001]
  • [Cites] Bioessays. 1998 Mar;20(3):215-26 [9631649.001]
  • [Cites] EMBO J. 1998 Sep 15;17(18):5497-508 [9736627.001]
  • [Cites] J Biol Chem. 1998 Dec 11;273(50):33660-6 [9837951.001]
  • [Cites] J Cell Biol. 1999 Jan 11;144(1):11-20 [9885240.001]
  • [Cites] Mol Cell Biol. 1999 Jul;19(7):5166-9 [10373565.001]
  • [Cites] Electrophoresis. 1999 Jul;20(10):2133-8 [10451126.001]
  • [Cites] BMC Pharmacol. 2004 Dec 2;4:31 [15575955.001]
  • [Cites] J Biol Chem. 2005 Apr 15;280(15):14709-15 [15677476.001]
  • [Cites] DNA Cell Biol. 2005 Jun;24(6):388-93 [15941391.001]
  • [Cites] Mol Cell Biol. 2005 Dec;25(24):10842-52 [16314509.001]
  • [Cites] Cell. 2006 Jan 27;124(2):287-99 [16439204.001]
  • [Cites] Cell. 2006 Jan 27;124(2):301-13 [16439205.001]
  • [Cites] Nat Genet. 2001 Mar;27(3):247-54 [11242102.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4550-5 [11389089.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):40652-8 [11546768.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3308-18 [11751636.001]
  • [Cites] J Cell Sci. 2002 Jan 1;115(Pt 1):153-64 [11801733.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40 [12042765.001]
  • [Cites] Genes Dev. 2002 Sep 15;16(18):2333-8 [12231622.001]
  • [Cites] J Mol Biol. 2003 Feb 7;326(1):93-103 [12547193.001]
  • [Cites] Mol Cell Biol. 2003 Aug;23(16):5706-15 [12897142.001]
  • (PMID = 20824055.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / RAD51C protein, human; EC 5.99.1.3 / DNA Topoisomerases, Type II
  • [Other-IDs] NLM/ PMC2932731
  •  go-up   go-down


57. Preoperative bi-fractionated accelerated radiation therapy for combined treatment of locally advanced rectal cancer in a consectutive series of unselected patients. Int Semin Surg Oncol; 2007 Sep 20;4:23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative bi-fractionated accelerated radiation therapy for combined treatment of locally advanced rectal cancer in a consectutive series of unselected patients.
  • METHODS: patients were screened following these eligibility criteria: histology-proven adenocarcinoma of the rectum; distal tumour extent at 12 cm or less from the anal verge; clinical stage T3-4/anyN, or anyT/N1-2; ECOG Performance Status 0-2.
  • Twenty-eight patients were stage II and 19 stage III.
  • CONCLUSION: bifractionated accelerated RT administered in the preoperative setting to patients bearing locally advanced rectal cancer is reliable and safe, as its immediate and late toxicity (mainly infectious) is acceptably low and long-term survivals are achievable.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1990 Feb;211(2):187-95 [2405793.001]
  • [Cites] Am J Surg. 1994 Jan;167(1):90-4; discussion 94-5 [8311145.001]
  • [Cites] Ann Surg. 1998 Feb;227(2):157-67 [9488510.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 1;92(5):388-96 [10699069.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):633-40 [11685026.001]
  • [Cites] Lancet. 2000 Jul 8;356(9224):93-6 [10963244.001]
  • [Cites] Ann Surg. 1994 Nov;220(5):676-82 [7979617.001]
  • [Cites] Br J Radiol. 1989 Aug;62(740):679-94 [2670032.001]
  • [Cites] Strahlenther Onkol. 2002 May;178(5):259-62 [12082685.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):964-8 [8813788.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):67-73 [7826163.001]
  • [Cites] Dis Colon Rectum. 1992 Aug;35(8):757-61 [1643999.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 May;10(5):593-8 [6735750.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]
  • [Cites] N Engl J Med. 1994 Aug 25;331(8):502-7 [8041415.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2396 [10561302.001]
  • [Cites] Strahlenther Onkol. 2004 Jan;180(1):5-14 [14704839.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):387-92 [1587760.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1291-304 [11684209.001]
  • [Cites] Clin Radiol. 1971 Apr;22(2):145-55 [5575251.001]
  • (PMID = 17883838.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2063497
  •  go-up   go-down


58. Qian HG, Shen J, Ma H, Ma HC, Su YH, Hao CY, Xing BC, Huang XF, Shou CC: Preliminary study on proteomics of gastric carcinoma and its clinical significance. World J Gastroenterol; 2005 Oct 28;11(40):6249-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary study on proteomics of gastric carcinoma and its clinical significance.
  • AIM: To explore the preliminary identification of serum protein pattern models that may be novel potential biomarkers in the detection of gastric cancer.
  • METHODS: A total of 130 serum samples, including 70 from patients with gastric cancer and 60 from healthy adults, were detected by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry (SELDI-TOF-MS).
  • Thirty serum samples of gastric cancer patients and 30 serum samples of healthy adults were grouped into the training group to build models, and the other 70 samples were used to test and evaluate the models.
  • The samples of the test group were judged only with their peaks' height and were separated into cancer group or healthy control group by BPS automatically and the judgments were checked with the histopathologic diagnosis of the samples.
  • Among them, nine mass peaks showed increased expression in patients with gastric cancer.
  • Analyzed by BPS, two peaks were chosen to build the model for gastric cancer detection.
  • Stage I/II gastric cancer samples of the test group were all judged correctly.
  • CONCLUSION: The novel biomarkers in serum and the established model could be potentially used in the detection of gastric cancer.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16419150.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC4320325
  •  go-up   go-down


59. Deschoolmeester V, Boeckx C, Baay M, Weyler J, Wuyts W, Van Marck E, Peeters M, Lardon F, Vermorken JB: KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis. Br J Cancer; 2010 Nov 9;103(10):1627-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis.
  • In this retrospective study, high-resolution melting analysis (HRMA) was validated and implemented for screening of 164 colorectal cancer (CRC) patients to detect KRAS hot-spot mutations and to evaluate its prognostic value.
  • In the Cox regression analysis, only when colon and rectal cancer were analysed separately, KRAS mutation was a negative predictor for OS in patients with rectal cancer and DFS in those with stage II colon cancer.
  • The KRAS mutation came forward as a negative predictive factor for OS in patients with rectal cancer and for DFS in stage II colon cancer patients.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Sep;81(2):190-3 [10496341.001]
  • [Cites] Oncol Rep. 2004 Dec;12(6):1221-5 [15547741.001]
  • [Cites] Ann Oncol. 2005 May;16 Suppl 4:iv50-55 [15923430.001]
  • [Cites] J Mol Diagn. 2005 Aug;7(3):413-21 [16049314.001]
  • [Cites] Gut. 2005 Sep;54(9):1283-6 [15843421.001]
  • [Cites] J Clin Lab Anal. 2006;20(2):52-61 [16538640.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):3992-5 [16618717.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5313-27 [17060676.001]
  • [Cites] Oncogene. 2007 Jan 4;26(1):158-63 [16953233.001]
  • [Cites] BMC Cancer. 2006;6:295 [17184525.001]
  • [Cites] Pathol Res Pract. 2007;203(7):489-97 [17629419.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2B):1405-10 [18505087.001]
  • [Cites] BMC Cancer. 2008;8:142 [18495026.001]
  • [Cites] Am J Clin Pathol. 2008 Aug;130(2):247-53 [18628094.001]
  • [Cites] Gene. 2008 Nov 1;423(2):188-93 [18692554.001]
  • [Cites] Eur J Cancer. 2008 Oct;44(15):2288-95 [18707864.001]
  • [Cites] Gut. 2009 Jan;58(1):90-6 [18832519.001]
  • [Cites] Oncologist. 2009 Jan;14(1):29-39 [19144681.001]
  • [Cites] J Mol Diagn. 2009 Mar;11(2):140-7 [19213871.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1155-61 [19190129.001]
  • [Cites] J Clin Oncol. 2009 Mar 1;27(7):1130-6 [19124802.001]
  • [Cites] Clin Adv Hematol Oncol. 2009 Jan;7(1):45-53, 64 [19274041.001]
  • [Cites] J Hematol Oncol. 2009;2:9 [19236713.001]
  • [Cites] Cancer Treat Rev. 2009 May;35(3):262-71 [19117687.001]
  • [Cites] J Clin Oncol. 2009 Apr 20;27(12):2091-6 [19188670.001]
  • [Cites] Oncologist. 2009 May;14(5):478-88 [19411318.001]
  • [Cites] BMC Cancer. 2009;9:145 [19439077.001]
  • [Cites] Cell Oncol. 2009;31(3):161-7 [19478384.001]
  • [Cites] J Clin Oncol. 2009 Jun 1;27(16):2622-9 [19398573.001]
  • [Cites] Pathol Res Pract. 2009;205(12):858-62 [19679400.001]
  • [Cites] Clin Cancer Res. 2009 Dec 1;15(23):7322-9 [19934290.001]
  • [Cites] Am J Ther. 2009 Nov-Dec;16(6):554-61 [19352138.001]
  • [Cites] J Clin Oncol. 2010 Jan 20;28(3):466-74 [20008640.001]
  • [Cites] Oncologist. 2010;15(4):390-404 [20350999.001]
  • [Cites] Anticancer Res. 2000 May-Jun;20(3A):1695-701 [10928094.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1193-7 [11097226.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):692-6 [11531254.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):917-23 [11535541.001]
  • [Cites] Curr Pharm Des. 2001 Nov;7(16):1581-94 [11562300.001]
  • [Cites] Ann Oncol. 2002 Sep;13(9):1438-46 [12196370.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1961-71 [12466110.001]
  • [Cites] Surg Clin North Am. 2002 Oct;82(5):891-904 [12507199.001]
  • [Cites] Ann Oncol. 2003 Jul;14(7):1026-38 [12853343.001]
  • [Cites] Int J Colorectal Dis. 2004 Jan;19(1):23-42 [12827409.001]
  • [Cites] Br J Surg. 2004 Oct;91(10):1275-91 [15382104.001]
  • [Cites] Gastroenterology. 1992 Apr;102(4 Pt 1):1136-41 [1551522.001]
  • [Cites] Arch Surg. 1993 May;128(5):526-31; discussion 531-2 [8489386.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):558-61 [8505985.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3376-8 [8012953.001]
  • [Cites] Eur J Cancer. 1996 Mar;32A(3):491-7 [8814697.001]
  • [Cites] Am J Surg. 1998 Mar;175(3):198-202 [9560119.001]
  • [Cites] J Natl Cancer Inst. 1998 May 6;90(9):675-84 [9586664.001]
  • (PMID = 20959826.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC2990591
  •  go-up   go-down


60. Jelski W, Mroczko B, Szmitkowski M: The diagnostic value of alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) measurement in the sera of colorectal cancer patients. Dig Dis Sci; 2010 Oct;55(10):2953-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic value of alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) measurement in the sera of colorectal cancer patients.
  • BACKGROUND: The activity of total alcohol dehydrogenase (ADH) and class I isoenzymes is significantly higher in colorectal cancer tissue than in healthy mucosa.
  • The activity of these enzymes in cancer cells is probably reflected in the sera and could thus be helpful for diagnosing colorectal cancer.
  • AIM: The aim of this study was to investigate a potential role of ADH and aldehyde dehydrogenase (ALDH) as tumor markers for colorectal cancer.
  • METHODS: Serum samples were taken from 182 patients with colorectal cancer before treatment and from 160 control subjects.
  • Total ADH activity and class III and IV isoenzymes were measured by photometric, but ALDH activity and ADH I and II by the fluorometric method, with class-specific fluorogenic substrates.
  • RESULTS: There was significant increase in the activity of ADH I isoenzyme and ADH total in the sera of colorectal cancer patients compared to the control.
  • The sensitivity and specificity of ADH I increased with the stage of the carcinoma.
  • CONCLUSION: The results suggest a potential role for ADH I as marker for colorectal cancer.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 1989 Oct 23;257(1):105-9 [2806555.001]
  • [Cites] Clin Chem. 1993 Nov;39(11 Pt 1):2298-304 [8222224.001]
  • [Cites] Clin Exp Med. 2006 Jun;6(2):89-93 [16820997.001]
  • [Cites] Anal Biochem. 1989 Apr;178(1):57-62 [2729580.001]
  • [Cites] Dig Dis Sci. 2004 Jun;49(6):977-81 [15309886.001]
  • [Cites] Clin Exp Med. 2007 Dec;7(4):154-7 [18188528.001]
  • [Cites] Anal Biochem. 1979 Oct 15;99(1):65-71 [231394.001]
  • [Cites] Dig Dis Sci. 2005 Jun;50(6):1019-24 [15986847.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Aug;16(4):775-810 [12418049.001]
  • [Cites] Digestion. 1996;57(2):105-8 [8785998.001]
  • [Cites] Clin Chem Lab Med. 2008;46(10):1423-8 [18844497.001]
  • [Cites] Clin Chim Acta. 2006 Sep;371(1-2):143-7 [16603145.001]
  • [Cites] Clin Chim Acta. 2007 May 1;380(1-2):208-12 [17368603.001]
  • [Cites] Alcohol Clin Exp Res. 1996 May;20(3):551-5 [8727253.001]
  • [Cites] Alcohol Clin Exp Res. 1996 Dec;20(9):1569-76 [8986205.001]
  • [Cites] Int J Colorectal Dis. 2007 Jan;22(1):33-8 [16520929.001]
  • [Cites] Clin Chem Lab Med. 2003 May;41(5):646-51 [12812262.001]
  • [Cites] BMJ. 2000 Feb 12;320(7232):424-7 [10669448.001]
  • (PMID = 20069455.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Isoenzymes; EC 1.1.1.1 / Alcohol Dehydrogenase; EC 1.2.1.3 / Aldehyde Dehydrogenase
  •  go-up   go-down


61. Gervaz P, Lavertu S, Kazemba B, Pemberton JH, Haddock MG, Gunderson LL: Sphincter-preserving radiation therapy for rectal cancer: a simulation study using three-dimensional computerized technology. Colorectal Dis; 2006 Sep;8(7):570-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sphincter-preserving radiation therapy for rectal cancer: a simulation study using three-dimensional computerized technology.
  • This approach provides, in theory, a means to selectively subtract the anal sphincter from the high-dose field of irradiation in patients with stage II and III adenocarcinomas of the mid-rectum scheduled for low anterior resection (LAR).
  • HYPOTHESIS: Implementation of 3DXRT with sphincter blocking may be a feasible strategy to reduce the dose of radiation distributed to the anal canal without reduction in the dose distribution to the gross tumour volume (GTV) plus adequate margins.
  • METHODS: Pretreatment simulation CT scans of 10 patients with rectal cancers located between 5 and 10 cm from the anal verge were retrieved from a computerized database.
  • Radiation oncologists and colorectal surgeons defined the contours of the GTV and the anal sphincter, respectively, on successive CT scan slices.
  • RESULTS: The mean distance of tumours from the anal verge was 6.3 cm.
  • The mean volume of the anal sphincter was 16.1 +/- 3.5 cm(3).
  • By comparison the mean dose distributed to the anal sphincter was dramatically reduced by using a sphincter block (33.2 +/- 12 Gy vs 6.4 +/- 4.1 Gy, P < 0.001).
  • CONCLUSION: During a course of radiotherapy for most low- or mid-rectal cancers, the anal canal is included within the field of irradiation with a mean dose distribution to the sphincter of 33 Gy.
  • Evaluation of 3DXRT with full sphincter block (mid-rectum) and partial sphincter block (distal rectum) is a feasible strategy to decrease the volume of anal sphincter carried to full dose without reduction in dose to the GTV.
  • This approach, by minimizing treatment-induced damage to the anal sphincter, might improve functional outcome of LAR.
  • [MeSH-major] Anal Canal / radiation effects. Computer Simulation. Radiotherapy Planning, Computer-Assisted. Rectal Neoplasms / radiotherapy. Rectal Neoplasms / therapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16919108.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


62. Bilimoria KY, Bentrem DJ, Rock CE, Stewart AK, Ko CY, Halverson A: Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum; 2009 Apr;52(4):624-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base.
  • PURPOSE: The objective of this study was to assess survival and prognostic factors for anal carcinoma in the population.
  • METHODS: Patients with squamous-cell carcinoma of the anal canal were identified from the National Cancer Data Base (1985-2000).
  • Concordance was calculated to assess agreement between American Joint Committee on Cancer stage and actual outcome.
  • RESULTS: Nineteen thousand one hundred ninety-nine patients with anal carcinoma were identified (Stage I, 25.3 percent; Stage II, 51.8 percent; Stage III, 17.1 percent; Stage IV, 5.7 percent).
  • The American Joint Committee on Cancer (6th edition) staging system provided good survival discrimination by stage: I, 69.5 percent; II, 59.0 percent; III, 40.6 percent; and IV, 18.7 percent (concordance index, 0.663).
  • On multivariable analysis, patients with anal carcinoma had a higher risk of death if they were male, >or=65 years old, black, living in lower median incomes areas, and had more advanced T stage tumors, nodal or distant metastases, or poorly differentiated cancers (P < 0.0001).
  • CONCLUSION: Although tumor characteristics and staging affect prognosis, patient factors, such as gender, race, and socioeconomic status, are also important prognostic factors for squamous-cell carcinoma of the anal canal.
  • [MeSH-major] Anus Neoplasms / mortality. Carcinoma, Squamous Cell / mortality


63. Vini L: Neoadjuvant radiochemotherapy for rectal cancer. Dig Dis; 2007;25(1):56-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant radiochemotherapy for rectal cancer.
  • During the past few decades, significant progress has been achieved in the management of rectal cancer with the introduction of total mesorectal excision.
  • Several recent studies show that 5-FU-based chemotherapy enhances tumor response to radiotherapy and preoperative chemoradiotherapy is being increasingly used for stage II and III disease.
  • [MeSH-minor] Anal Canal. Combined Modality Therapy. Humans. Preoperative Care. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Rectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 17384509.001).
  • [ISSN] 0257-2753
  • [Journal-full-title] Digestive diseases (Basel, Switzerland)
  • [ISO-abbreviation] Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


64. Weiser MR, Quah HM, Shia J, Guillem JG, Paty PB, Temple LK, Goodman KA, Minsky BD, Wong WD: Sphincter preservation in low rectal cancer is facilitated by preoperative chemoradiation and intersphincteric dissection. Ann Surg; 2009 Feb;249(2):236-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sphincter preservation in low rectal cancer is facilitated by preoperative chemoradiation and intersphincteric dissection.
  • OBJECTIVE: The aim of this study was to evaluate oncologic outcome in patients with locally advanced distal rectal cancer treated with preoperative chemoradiation followed by low anterior resection (LAR)/stapled coloanal anastomosis, LAR/intersphincteric dissection/hand-sewn coloanal anastomosis, or abdominoperineal resection (APR).
  • SUMMARY BACKGROUND DATA: Distal rectal cancer presents a surgical challenge, and the goals of treatment often include tumor eradication without sacrifice of the anal sphincters.
  • The technique of intersphincteric resection removes the internal anal sphincter to gain additional distal rectal margin in hopes of avoiding a permanent stoma.
  • METHODS: We analyzed 148 patients with stage II and III rectal cancers (endorectal ultrasound staged uT3-4 and/or uN1) located < or =6 cm from the anal verge, treated by preoperative chemoradiation and total mesorectal excision from 1998 to 2004.
  • CONCLUSIONS: In low rectal cancer, sphincter preservation is facilitated by a significant response to preoperative chemoradiation and intersphincteric resection, without compromise of margins or outcome.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / physiopathology. Anal Canal / surgery. Antineoplastic Agents / administration & dosage. Colectomy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212176.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


65. Deschoolmeester V, Baay M, Wuyts W, Van Marck E, Pelckmans P, Lardon F, Vermorken JB: Comparison of three commonly used PCR-based techniques to analyze MSI status in sporadic colorectal cancer. J Clin Lab Anal; 2006;20(2):52-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of three commonly used PCR-based techniques to analyze MSI status in sporadic colorectal cancer.
  • Several retrospective studies have shown that a high level of microsatellite instability (MSI-H) is an important prognostic factor of a more favorable outcome in stage II and III colorectal cancer (CRC) patients.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16538640.001).
  • [ISSN] 0887-8013
  • [Journal-full-title] Journal of clinical laboratory analysis
  • [ISO-abbreviation] J. Clin. Lab. Anal.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


66. Boya P, González-Polo RA, Casares N, Perfettini JL, Dessen P, Larochette N, Métivier D, Meley D, Souquere S, Yoshimori T, Pierron G, Codogno P, Kroemer G: Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol; 2005 Feb;25(3):1025-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Under conditions in which the fusion between lysosomes and autophagosomes was inhibited, the formation of autophagic vacuoles was enhanced at a preapoptotic stage, as indicated by accumulation of LC3-II protein, ultrastructural studies, and an increase in the acidic vacuolar compartment.

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. MONENSIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1996 Jun 14;271(24):14361-70 [8662952.001]
  • [Cites] J Biol Chem. 1996 Nov 8;271(45):28593-600 [8910489.001]
  • [Cites] Eur J Biochem. 1997 Jan 15;243(1-2):240-6 [9030745.001]
  • [Cites] Cell Struct Funct. 1998 Feb;23(1):33-42 [9639028.001]
  • [Cites] Anal Chem. 2003 May 1;75(9):2123-30 [12720351.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2103-8 [12727826.001]
  • [Cites] J Biol Chem. 2003 May 9;278(19):16667-74 [12609989.001]
  • [Cites] J Exp Med. 2003 May 19;197(10):1323-34 [12756268.001]
  • [Cites] Oncogene. 2003 Jun 19;22(25):3927-36 [12813466.001]
  • [Cites] Cell Death Differ. 2003 Jul;10(7):798-807 [12815463.001]
  • [Cites] Oncogene. 2003 Sep 18;22(40):6220-30 [13679861.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):39517-26 [12890687.001]
  • [Cites] Dev Cell. 2003 Oct;5(4):539-45 [14536056.001]
  • [Cites] Trends Cell Biol. 1998 Jul;8(7):267-71 [9714597.001]
  • [Cites] Biochim Biophys Acta. 1998 Aug 10;1366(1-2):177-96 [9714796.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1309-12 [9721092.001]
  • [Cites] J Virol. 1998 Nov;72(11):8586-96 [9765397.001]
  • [Cites] J Immunol Methods. 2002 Jul 1;265(1-2):39-47 [12072177.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15077-82 [14657337.001]
  • [Cites] J Clin Invest. 2003 Dec;112(12):1809-20 [14638851.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 9;313(2):453-8 [14684184.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6316-25 [14695130.001]
  • [Cites] Development. 2004 Jan;131(2):275-84 [14668412.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):422-4 [14706333.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):696-703 [14744787.001]
  • [Cites] Cell Death Differ. 2004 Apr;11(4):448-57 [14713959.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12536-41 [10535957.001]
  • [Cites] Nature. 1999 Dec 9;402(6762):672-6 [10604474.001]
  • [Cites] Nature. 2000 Jan 6;403(6765):98-103 [10638761.001]
  • [Cites] J Cell Biol. 2000 Mar 20;148(6):1141-49 [10725327.001]
  • [Cites] Nat Med. 2000 May;6(5):513-9 [10802706.001]
  • [Cites] Methods Enzymol. 2000;322:208-13 [10914018.001]
  • [Cites] J Cell Biol. 2000 Aug 21;150(4):741-54 [10953000.001]
  • [Cites] Nature. 2000 Aug 24;406(6798):902-6 [10972293.001]
  • [Cites] Annu Rev Biochem. 2000;69:303-42 [10966461.001]
  • [Cites] J Exp Med. 2000 Oct 16;192(8):1081-92 [11034598.001]
  • [Cites] EMBO J. 2000 Nov 1;19(21):5720-8 [11060023.001]
  • [Cites] Science. 2000 Dec 1;290(5497):1717-21 [11099404.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):439-44 [11212227.001]
  • [Cites] Cell Death Differ. 2000 Dec;7(12):1263-9 [11175264.001]
  • [Cites] J Cell Biol. 2001 Feb 19;152(4):657-68 [11266458.001]
  • [Cites] Curr Biol. 2001 Mar 6;11(5):361-5 [11267874.001]
  • [Cites] EMBO Rep. 2001 Apr;2(4):330-5 [11306555.001]
  • [Cites] Science. 2001 Apr 27;292(5517):727-30 [11326099.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Aug;2(8):589-98 [11483992.001]
  • [Cites] Cell Death Differ. 2001 Jun;8(6):569-81 [11536007.001]
  • [Cites] Nat Struct Biol. 2001 Oct;8(10):824-6 [11573080.001]
  • [Cites] FASEB J. 2001 Oct;15(12):2286-7 [11511528.001]
  • [Cites] Genes Dev. 2001 Nov 15;15(22):2922-33 [11711427.001]
  • [Cites] Nat Cell Biol. 2001 Nov;3(11):E255-63 [11715037.001]
  • [Cites] Oncogene. 2001 Nov 15;20(52):7579-87 [11753636.001]
  • [Cites] J Cell Sci. 2001 Dec;114(Pt 24):4557-65 [11792820.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Feb;3(2):112-21 [11836513.001]
  • [Cites] Trends Endocrinol Metab. 2002 Mar;13(2):75-8 [11854022.001]
  • [Cites] J Cell Biol. 2002 Apr 29;157(3):455-68 [11980920.001]
  • [Cites] J Cell Biol. 2002 Aug 5;158(3):507-17 [12147675.001]
  • [Cites] Science. 2002 Aug 23;297(5585):1352-4 [12193789.001]
  • [Cites] Science. 2002 Sep 13;297(5588):1873-7 [12228718.001]
  • [Cites] Neuron. 2002 Aug 29;35(5):921-33 [12372286.001]
  • [Cites] J Neurosci. 2002 Oct 15;22(20):8951-60 [12388602.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9 [12391322.001]
  • [Cites] Eukaryot Cell. 2002 Feb;1(1):11-21 [12455967.001]
  • [Cites] Curr Opin Cell Biol. 2002 Dec;14(6):727-33 [12473346.001]
  • [Cites] Mol Cell Biol. 2003 Feb;23(3):777-90 [12529384.001]
  • [Cites] Curr Biol. 2003 Feb 18;13(4):350-7 [12593803.001]
  • [Cites] Curr Biol. 2003 Feb 18;13(4):358-63 [12593804.001]
  • [Cites] Genes Dev. 2003 Oct 15;17(20):2481-95 [14561771.001]
  • [Cites] J Biol Chem. 2003 Oct 24;278(43):41938-46 [12917395.001]
  • [Cites] J Cell Biol. 2003 Dec 8;163(5):1123-31 [14662750.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):13496-505 [14726525.001]
  • [Cites] J Biol Chem. 2004 May 14;279(20):20699-707 [14742431.001]
  • [Cites] Br J Cancer. 1972 Aug;26(4):239-57 [4561027.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):1889-92 [6952238.001]
  • [Cites] Exp Cell Res. 1983 Nov;149(1):27-35 [6641796.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Nov;85(21):7972-6 [2973058.001]
  • [Cites] J Biol Chem. 1991 Sep 15;266(26):17707-12 [1832676.001]
  • [Cites] FEBS Lett. 1993 Oct 25;333(1-2):169-74 [8224160.001]
  • (PMID = 15657430.001).
  • [ISSN] 0270-7306
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Atg5 protein, mouse; 0 / Becn1 protein, mouse; 0 / Caspase Inhibitors; 0 / Enzyme Inhibitors; 0 / Immediate-Early Proteins; 0 / Microtubule-Associated Proteins; 0 / Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Small Interfering; 0 / UL37 protein, Human herpesvirus 5; 0 / Viral Proteins; 5142-23-4 / 3-methyladenine; 906O0YJ6ZP / Monensin; EC 3.4.22.- / Caspases; JAC85A2161 / Adenine
  • [Other-IDs] NLM/ PMC543994
  •  go-up   go-down


67. Chamlou R, Parc Y, Simon T, Bennis M, Dehni N, Parc R, Tiret E: Long-term results of intersphincteric resection for low rectal cancer. Ann Surg; 2007 Dec;246(6):916-21; discussion 921-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of intersphincteric resection for low rectal cancer.
  • INTRODUCTION: In the treatment of very low rectal cancer, a distal resection margin of more than 1 cm can be obtained by partial internal sphincteric resection, allowing a sphincter preserving surgery.
  • Thus, intersphincteric resection (ISR) has been proposed as an alternative to abdominoperineal resection for selected low rectal cancer.
  • Cancer-related survival and locoregional recurrence rates were calculated using the Kaplan-Meier method.
  • RESULTS: Ninety patients (59 males, 31 females) with a tumor at a median distance of 35 mm (range, 22-52) from the anal verge had an ISR.
  • Thirteen patients (14.4%) died of cancer recurrence.
  • In univariate analysis, overall survival was significantly influenced by pTNM stage and T stage (pT 1-2 vs. 3-4: P = 0.008 and stage I-II vs. III-IV: P = 0.03).
  • After adjustment for age, gender, tumor level, and pTNM stage, preoperative radiotherapy was the only factor associated with a risk of fecal incontinence [OR (IC 95%) = 3.1 (1.0-9.0), P = 0.04].
  • [MeSH-major] Adenocarcinoma / epidemiology. Anal Canal / surgery. Colectomy / methods. Rectal Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043092.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Li SY, Liang ZJ, Yuan SJ, Yu B, Chen G, Zuo FY, Bai X, Chen G, Wei XJ, Xu YS, Cui W: [Clinical experience of 371 cases of sphincter-preservation with telescopic anastomosis after radical excision for low-middle rectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Apr;13(4):263-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical experience of 371 cases of sphincter-preservation with telescopic anastomosis after radical excision for low-middle rectal cancer].
  • OBJECTIVE: To evaluate the clinical efficacy, feasibility and safety of sphincter-preservation with telescopic anastomosis of colon and rectal mucosa in low-middle rectal cancer.
  • METHODS: A retrospective analysis was carried out in 371 patients with low-middle rectal cancer in whom telescopic anastomosis was used.
  • The lower margins of the tumors located between 5-8 cm from the anal verge.
  • According to the Duke's stage classification, 120 were TNM stage I, 222 stage II, 26 stage III, and 3 stage IV.
  • CONCLUSION: The sphincter-preservation with telescopic anastomosis procedure is safe and effective for low-middle rectal cancer, and the sphincter function can be well-preserved.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Anastomosis, Surgical / methods. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20422480.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


69. Oehler-Jänne C, Seifert B, Lütolf UM, Studer G, Glanzmann C, Ciernik IF: Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma. Brachytherapy; 2007 Jul-Sep;6(3):218-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma.
  • PURPOSE: To evaluate the outcome after definitive whole pelvis external beam radiotherapy (EBRT) followed by brachytherapy (BT) boost after treatment break vs. external beam boost without break in the treatment of anal carcinoma.
  • METHODS AND MATERIALS: Eighty-one consecutive patients with invasive anal carcinoma were analyzed retrospectively.
  • Concomitant chemotherapy (CT) with mitomycin C was applied during whole pelvis EBRT depending on tumor stage.
  • Pattern of care, local disease control (LC), cancer-specific survival (CSS), overall survival (OS), toxicity, and quality of life (QOL) were assessed.
  • In early stage tumors, (192)Ir-HDR BT boost with CT resulted in a 5-year LC and CSS of 100%.
  • In all patients, BT boost did not result in improved LC, OS, and CSS compared with EBRT boost, despite stage and treatment bias favoring small tumors to be treated with BT.
  • Subgroup analysis of Stages I and II disease revealed no significant improvement after BT boost compared with EBRT boost.
  • BT boost is most beneficial in early stage tumors but the advantage of BT seems to be limited due to its invasiveness, doctor dependence, and logistic circumstances.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Brachytherapy / instrumentation. Carcinoma / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17681244.001).
  • [ISSN] 1538-4721
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


71. Selvindos PB, Ho YH: Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis. Dis Colon Rectum; 2008 Nov;51(11):1710-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis.
  • PURPOSE: Optimal treatment of mid to distal rectal cancers includes total mesorectal excision for oncologic clearance and, where reanastomosis is feasible, a colonic J-pouch-anal anastomosis improves bowel function.
  • Bowel continuity was restored by an intracoporeal double-cross stapled colonic J-pouch-anal anastomosis, but where not possible a coloplasty with pull-through handsewn coloanal anastomosis was performed.
  • The indications were adenocarcinoma (n = 51), squamous-cell carcinoma of rectum (n = 1), dermoid tumor of mesorectum (n = 1), large villous adenoma (n = 1), and carcinoid with local lymph node metastases (n = 1).
  • The adenocarcinomas were a median distance of 6 (3-12) cm from the anal verge.
  • The histologic grading or the adenocarcinoma patients were: Stage I, n = 14; Stage II, n = 23; Stage III, n = 11; Stage IV, n = 3.
  • The level of the coloanal anastomosis was a median 3.5 (0-4.5) cm from the anal verge; a coloanal pull-through anastomosis was required in one patient who had a distal cancer.
  • Four other patients had smaller pelvic collections that resolved with antibiotics; pelvic collections were associated with advanced stage of cancer (P = 0.047).
  • This brought the rectum proximally and anteriorly, aiding with the laparoscopic stapler transection of the distal rectum, especially if the cancer was distal, the patient was obese, and the pelvis was narrow.
  • Further randomized, controlled studies that include assessing five-year cancer survival/recurrence, pelvic nerve dysfunction, and bowel function are needed before laparoscopic ultralow anterior resection becomes widely accepted.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Colonic Pouches. Laparoscopy / methods. Proctocolectomy, Restorative / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18679748.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Interactive Tutorial
  • [Publication-country] United States
  •  go-up   go-down


72. Ballonoff A, Kavanagh B, McCarter M, Kane M, Pearlman N, Nash R, Shah RJ, Raben D, Schefter TE: Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial. Am J Clin Oncol; 2008 Jun;31(3):264-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial.
  • OBJECTIVES: A prospective phase II trial was conducted to evaluate the feasibility, safety, and pathologic response rate of preoperative capecitabine and accelerated synchronous integrated boost (SIB) intensity-modulated radiotherapy (IMRT) in patients with locally advanced rectal cancer.
  • METHODS: Consenting operable patients with stage II or III adenocarcinoma of the rectum received capecitabine (825 mg/m2 PO BID, 5 days/wk x 5 weeks) and SIB-IMRT delivering 55 Gy (2.2 Gy/fraction) to the gross tumor while simultaneously delivering 45 Gy (1.8 Gy/fraction) to the regional lymph nodes and areas at risk for harboring microscopic disease.
  • A single pathologist analyzed the resected tumor's TNM stage and Mandard regression/response scores.
  • RESULTS: Ten subjects were enrolled, 2 of which were ineligible (1 screening failure and 1 unrelated cerebrovascular accident occurring early in treatment).
  • Of 3 patients who had tumors within 5 cm of the anal verge, 2 underwent sphincter-sparing procedures.
  • CONCLUSIONS: Preoperative chemoradiation with capecitabine and SIB-IMRT is well tolerated and results in an encouraging pCR rate for patients with locally advanced rectal cancer.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18525306.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


73. Bierie B, Gorska AE, Stover DG, Moses HL: TGF-beta promotes cell death and suppresses lactation during the second stage of mammary involution. J Cell Physiol; 2009 Apr;219(1):57-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TGF-beta promotes cell death and suppresses lactation during the second stage of mammary involution.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] J Biol Chem. 2008 Jan 18;283(3):1293-307 [18024957.001]
  • [Cites] Science. 2007 Feb 9;315(5813):840-3 [17234915.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3444-9 [10716706.001]
  • [Cites] Development. 2000 Jul;127(14):3107-18 [10862748.001]
  • [Cites] J Cell Biol. 2001 Nov 12;155(4):531-42 [11706048.001]
  • [Cites] Transgenic Res. 2001 Dec;10(6):545-53 [11817542.001]
  • [Cites] Genesis. 2002 Feb;32(2):73-5 [11857781.001]
  • [Cites] Cell Growth Differ. 2002 Mar;13(3):123-30 [11959813.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):2081-93 [12057913.001]
  • [Cites] Endocrinology. 2002 Sep;143(9):3641-50 [12193580.001]
  • [Cites] J Histochem Cytochem. 2003 May;51(5):555-65 [12704203.001]
  • [Cites] Cell. 2003 May 2;113(3):301-14 [12732139.001]
  • [Cites] Eur J Cell Biol. 2003 Jun;82(6):303-12 [12868598.001]
  • [Cites] Development. 2003 Nov;130(21):5257-68 [12954715.001]
  • [Cites] Am J Pathol. 2003 Oct;163(4):1539-49 [14507660.001]
  • [Cites] Development. 2003 Dec;130(24):6143-53 [14597578.001]
  • [Cites] Mol Endocrinol. 2004 May;18(5):1171-84 [14963111.001]
  • [Cites] Cancer Lett. 2004 Sep 30;213(2):129-38 [15327827.001]
  • [Cites] Oncogene. 2004 Sep 9;23(41):6980-5 [15286714.001]
  • [Cites] Science. 1987 Jul 17;237(4812):291-3 [3474783.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Dev Biol. 1989 Sep;135(1):20-30 [2767334.001]
  • [Cites] Growth Factors. 1990;4(1):9-15 [2085442.001]
  • [Cites] Development. 1991 Nov;113(3):867-78 [1821856.001]
  • [Cites] J Cell Biol. 1993 Jan;120(1):245-51 [8416990.001]
  • [Cites] J Cell Biol. 1993 Jan;120(1):253-60 [8416992.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):770-4 [8421714.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):9944-8 [8234339.001]
  • [Cites] Biochem J. 1994 Dec 1;304 ( Pt 2):333-6 [7998965.001]
  • [Cites] Dev Biol. 1995 Mar;168(1):47-61 [7883078.001]
  • [Cites] Nat Genet. 1995 Dec;11(4):409-14 [7493021.001]
  • [Cites] Nucleic Acids Res. 1997 Nov 1;25(21):4323-30 [9336464.001]
  • [Cites] Cell Growth Differ. 1998 Mar;9(3):229-38 [9543389.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):70-1 [9916792.001]
  • [Cites] Genes Dev. 1999 Oct 1;13(19):2604-16 [10521404.001]
  • [Cites] Breast Cancer Res. 2004;6(2):R75-91 [14979920.001]
  • [Cites] Breast Cancer Res. 2004;6(2):R92-109 [14979921.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2296-302 [15781643.001]
  • [Cites] Development. 2005 Nov;132(21):4675-85 [16192306.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):1809-19 [18339861.001]
  • (PMID = 19086032.001).
  • [ISSN] 1097-4652
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA085492-06A1; United States / NCI NIH HHS / CA / CA085492-06; United States / NCI NIH HHS / CA / CA126505-05S1; United States / NCI NIH HHS / CA / R01 CA102162; United States / NCI NIH HHS / CA / U54 CA126505; United States / NCI NIH HHS / CA / R01 CA085492-06A1; United States / NCI NIH HHS / CA / CA126505; United States / NCI NIH HHS / CA / U54 CA126505-05S1; United States / NCI NIH HHS / CA / R01 CA085492; United States / NCI NIH HHS / CA / R01 CA102162-09; United States / NCI NIH HHS / CA / CA102162
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Milk Proteins; 0 / Receptors, Transforming Growth Factor beta; 0 / STAT3 Transcription Factor; 0 / Sodium-Phosphate Cotransporter Proteins, Type IIb; 0 / Stat3 protein, mouse; 0 / Transforming Growth Factor beta; 0 / Tumor Suppressor Protein p53; 0 / whey acidic proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  • [Other-IDs] NLM/ NIHMS266614; NLM/ PMC3038423
  •  go-up   go-down


74. Sinha S, Sinha N, Bandyopadhyay R, Mondal SK: Robinson's cytological grading on aspirates of breast carcinoma: Correlation with Bloom Richardson's histological grading. J Cytol; 2009 Oct;26(4):140-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robinson's cytological grading on aspirates of breast carcinoma: Correlation with Bloom Richardson's histological grading.
  • BACKGROUND: Cytological grading (CG) on aspirates of breast carcinoma is a useful tool for surgical maneuver and prognosis.
  • AIMS: An endeavor was made to use CG on aspirates of breast carcinoma using Robinson's grade and to correlate it with Bloom Richardsons' histopathological grading.
  • MATERIALS AND METHODS: A total of 59 patients of breast carcinoma, aged 28-57 years, were aspirated and the smears were graded using Robinson's criteria.
  • For grade I and II tumors, there was substantial strength of agreement between cytology and histopathology, while in grade III, the concordance was nearly perfect.
  • Lymph node metastasis was observed in three with cytological grade II, 28 of grade III and none of grade I.
  • All grade I had stage A, two of grade II had stage B, while all grade III had either stage B or stage C disease.
  • CONCLUSIONS: Thus, CG of breast carcinoma correlates well with histopathological grading and may well be useful as a prognostic marker.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Anal Quant Cytol Histol. 1987 Dec;9(6):480-4 [2829937.001]
  • [Cites] Lancet. 1994 Apr 16;343(8903):947-9 [7909010.001]
  • [Cites] Diagn Cytopathol. 1997 Apr;16(4):295-311 [9143822.001]
  • [Cites] Cancer. 1997 Feb 25;81(1):16-21 [9100536.001]
  • [Cites] Diagn Cytopathol. 1995 Oct;13(3):260-5 [8575287.001]
  • [Cites] Diagn Cytopathol. 1995 Dec;13(5):388-95 [8834313.001]
  • [Cites] Diagn Cytopathol. 1996 Aug;15(2):116-20 [8872432.001]
  • [Cites] Diagn Cytopathol. 1994;10(3):203-8 [8050325.001]
  • (PMID = 21938177.001).
  • [ISSN] 0974-5165
  • [Journal-full-title] Journal of cytology
  • [ISO-abbreviation] J Cytol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3167998
  • [Keywords] NOTNLM ; Bloom Richardson's grading / Breast carcinoma / Robinson's grading / fine needle aspiration cytology
  •  go-up   go-down


75. Ohnishi ST, Nishino K, Uchiyama S, Ohnishi T, Yamaguchi M: Ki-energy (life-energy) stimulates osteoblastic cells and inhibits the formation of osteoclast-like cells in bone cell culture models. Evid Based Complement Alternat Med; 2007 Jun;4(2):225-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed a reverse transcription-polymerase chain reaction (RT-PCR) study using these cells, but the mRNA expressions did not change significantly. (ii) After cells were incubated for 72 h without Ki-exposure (in the presence of FBS), they were further cultured for 48 h (in the absence of FBS) to promote differentiation.
  • At the beginning of the second culture stage, Ki was applied once for 10 min.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549240.001).
  • [ISSN] 1741-427X
  • [Journal-full-title] Evidence-based complementary and alternative medicine : eCAM
  • [ISO-abbreviation] Evid Based Complement Alternat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1876607
  •  go-up   go-down


76. Hessien MH, El-Sharkawi IM, El-Barbary AA, El-Beltagy DM, Snyder N: Non-invasive index of liver fibrosis induced by alcohol, thioacetamide and Schistosomal infection in mice. BMC Gastroenterol; 2010;10:53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The following methods were employed: (i) The METAVIR system was utilized to grade and stage liver inflammation and fibosis;.
  • (ii) Determination of hepatic hydroxyproline and collagen; and (iii) Derivation of a new hepatic fibrosis index from the induced changes, and its prospective validation in a group of 70 mice.
  • These parameters were highly correlated with both the histological stage and the grade.
  • They were combined in a logarithmic formula, which non-invasively scores the severity of liver fibrosis through a range (0 to 2), starting with healthy liver (corresponding to stage 0) to advanced fibrosis (corresponding stage 3).Receiver operating characteristic curves (ROC) for the accuracy of the index to predict the histological stages demonstrated that the areas under the curve (AUC) were 0.954, 0.979 and 0.99 for index values corresponding to histological stages 1, 2 and 3, respectively.
  • Also, the index was correlated with stage and grade, (0.947 and 0.859, respectively).
  • The AUROC was 0.869 and there was good correlation with the stage of fibrosis and grade of inflammation.

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • Hazardous Substances Data Bank. THIOACETAMIDE .
  • Hazardous Substances Data Bank. ETHANOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 1999 Dec;30(6):1529-30 [10610352.001]
  • [Cites] Hepatology. 2009 Jun;49(6):1821-7 [19291784.001]
  • [Cites] N Engl J Med. 2001 Feb 15;344(7):495-500 [11172192.001]
  • [Cites] Lancet. 2001 Apr 7;357(9262):1069-75 [11297957.001]
  • [Cites] Hum Exp Toxicol. 2001 May;20(5):251-4 [11476157.001]
  • [Cites] Hepatology. 2002 Oct;36(4 Pt 1):986-92 [12297848.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2614-8 [12385448.001]
  • [Cites] Hepatology. 1997 Dec;26(6):1393-8 [9397976.001]
  • [Cites] Hepatology. 1999 Jan;29(1):14-20 [9862843.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] J Hepatol. 2003 Aug;39(2):222-30 [12873819.001]
  • [Cites] J Hepatol. 2003 Aug;39(2):239-44 [12873821.001]
  • [Cites] Hepatology. 2003 Aug;38(2):518-26 [12883497.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2003 Feb;2(1):69-72 [14607650.001]
  • [Cites] Anal Biochem. 1979 Jun;95(2):351-8 [36810.001]
  • [Cites] Res Exp Med (Berl). 1980;177(3):201-11 [6449727.001]
  • [Cites] Pharmacol Ther. 1985;29(1):129-56 [3914644.001]
  • [Cites] Pharmacol Toxicol. 1987 Mar;60(3):171-4 [3588511.001]
  • [Cites] Exp Pathol. 1988;34(4):229-36 [2853079.001]
  • [Cites] Hepatology. 1996 Aug;24(2):289-93 [8690394.001]
  • [Cites] Arch Biochem Biophys. 1959 May;82(1):70-7 [13650640.001]
  • [Cites] Gastroenterology. 2005 Feb;128(2):343-50 [15685546.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Feb;3(2):167-74 [15704051.001]
  • [Cites] Alcohol Clin Exp Res. 2006 Aug;30(8):1429-35 [16899047.001]
  • [Cites] J Hepatol. 2007 May;46(5):775-82 [17321634.001]
  • [Cites] Clin Chim Acta. 2007 Jun;381(2):119-23 [17442291.001]
  • [Cites] Rinsho Byori. 2007 Aug;55(8):751-7 [17882797.001]
  • [Cites] Hepatology. 2008 Feb;47(2):455-60 [18038452.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):2033-42 [18339886.001]
  • [Cites] Chest. 2008 May;133(5):1101-6 [18071010.001]
  • [Cites] Anal Biochem. 2000 Oct 1;285(1):16-20 [10998259.001]
  • (PMID = 20515488.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 075T165X8M / Thioacetamide; 3K9958V90M / Ethanol; 9007-34-5 / Collagen; EC 2.3.2.2 / gamma-Glutamyltransferase; GAN16C9B8O / Glutathione; RFM9X3LJ49 / Bilirubin; RMB44WO89X / Hydroxyproline
  • [Other-IDs] NLM/ PMC2894747
  •  go-up   go-down


77. Ceelen W, Boterberg T, Pattyn P, van Eijkeren M, Gillardin JM, Demetter P, Smeets P, Van Damme N, Monsaert E, Peeters M: Neoadjuvant chemoradiation versus hyperfractionated accelerated radiotherapy in locally advanced rectal cancer. Ann Surg Oncol; 2007 Feb;14(2):424-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemoradiation versus hyperfractionated accelerated radiotherapy in locally advanced rectal cancer.
  • BACKGROUND: Neoadjuvant therapy is increasingly used in resectable locally advanced rectal cancer.
  • METHODS: Clinical, pathological, and survival data were obtained from patients with resectable stage II or III rectal cancer within 7 cm from the anal verge.
  • The mean distance from the anal verge was 5.8 cm (HART) versus 4.9 cm (CRT).

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17096057.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Natarajan L, Pu M, Parker BA, Thomson CA, Caan BJ, Flatt SW, Madlensky L, Hajek RA, Al-Delaimy WK, Saquib N, Gold EB, Pierce JP: Time-varying effects of prognostic factors associated with disease-free survival in breast cancer. Am J Epidemiol; 2009 Jun 15;169(12):1463-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time-varying effects of prognostic factors associated with disease-free survival in breast cancer.
  • Early detection and effective treatments have dramatically improved breast cancer survivorship, yet the risk of relapse persists even 15 years after the initial diagnosis.
  • It is important to identify prognostic factors for late breast cancer events.
  • The authors investigated time-varying effects of tumor characteristics on breast-cancer-free survival using data on 3,088 breast cancer survivors from 4 US states who participated in a randomized dietary intervention trial in 1995-2006, with maximum follow-up through 15 years (median, 9 years).
  • Having a stage II or III tumor was associated with a 3-fold higher hazard of breast cancer than having a stage I tumor during the first 2.5 years after diagnosis; this hazard ratio decreased to 2.1 after 7.7 years, but higher tumor stage remained a significant risk factor.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Radiat Oncol. 2002 Oct;12(4):319-28 [12382190.001]
  • [Cites] JAMA. 2007 Jul 18;298(3):289-98 [17635889.001]
  • [Cites] Breast Cancer Res Treat. 2003 Mar;78(1):105-18 [12611463.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1331-6 [15042664.001]
  • [Cites] Biometrics. 2004 Jun;60(2):344-51 [15180659.001]
  • [Cites] Biometrics. 1989 Mar;45(1):135-44 [2720049.001]
  • [Cites] Lifetime Data Anal. 1997;3(1):13-25 [9384623.001]
  • [Cites] Breast Cancer Res Treat. 1998;52(1-3):227-37 [10066085.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] JAMA. 2006 Apr 12;295(14):1658-67 [16609087.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] Stat Med. 2006 Aug 30;25(16):2831-45 [16158396.001]
  • [Cites] Biom J. 2007 Jun;49(3):453-73 [17623349.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4168-74 [18593996.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 20;100(16):1179-83 [18695137.001]
  • [Cites] Breast Cancer Res Treat. 2009 Aug;116(3):595-602 [18830816.001]
  • [Cites] Control Clin Trials. 2002 Dec;23(6):728-56 [12505249.001]
  • (PMID = 19403844.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA069375-09; United States / NCI NIH HHS / CA / R01 CA069375-06S1; United States / NCRR NIH HHS / RR / M01 RR000079; United States / NCI NIH HHS / CA / R01 CA069375-04S3; United States / NCI NIH HHS / CA / R01 CA069375-04S4; United States / NCI NIH HHS / CA / R01 CA069375-05S5; United States / NCRR NIH HHS / RR / M01-RR00827; United States / NCI NIH HHS / CA / R01 CA069375-06S2; United States / NCI NIH HHS / CA / R01 CA069375-05S1; United States / NCI NIH HHS / CA / R01 CA069375-03S1; United States / NCI NIH HHS / CA / CA 69375; United States / NCI NIH HHS / CA / R01 CA069375-04S2; United States / NCI NIH HHS / CA / R01 CA069375-08; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCI NIH HHS / CA / R01 CA069375-04; United States / NCI NIH HHS / CA / R01 CA069375-05; United States / NCI NIH HHS / CA / R01 CA069375-02; United States / NCI NIH HHS / CA / CA069375-08; United States / NCRR NIH HHS / RR / M01-RR00070; United States / NCI NIH HHS / CA / R01 CA069375-06; United States / NCI NIH HHS / CA / R01 CA069375-10; United States / NCI NIH HHS / CA / R01 CA069375-05S4; United States / NCI NIH HHS / CA / R01 CA069375-03; United States / NCI NIH HHS / CA / R01 CA069375-07; United States / NCI NIH HHS / CA / R01 CA069375-05S2; United States / NCRR NIH HHS / RR / M01 RR000070; United States / NCI NIH HHS / CA / R01 CA069375-04S1; United States / NCRR NIH HHS / RR / M01 RR000827; United States / NCI NIH HHS / CA / R01 CA069375-02S1; United States / NCI NIH HHS / CA / R01 CA069375; United States / NCI NIH HHS / CA / R01 CA069375-05S3
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2733768
  •  go-up   go-down


79. Hosein PJ, Rocha-Lima CM: Role of combined-modality therapy in the management of locally advanced rectal cancer. Clin Colorectal Cancer; 2008 Nov;7(6):369-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of combined-modality therapy in the management of locally advanced rectal cancer.
  • The majority of patients with nonmetastatic rectal cancer are candidates for an aggressive multimodality approach with curative intent.
  • Multidisciplinary preoperative patient evaluation, better staging techniques, neoadjuvant chemoradiation, acceptance of shorter distal rectal margins, and transanal excision of T1 N0 rectal tumors in close proximity to the anal sphincter have resulted in decreased rates of abdominoperineal resections.
  • Preoperative and postoperative radiation therapy was shown to decrease the local recurrence rate, but not overall survival, in patients with resectable rectal cancer.
  • For patients with stage II or III disease, neoadjuvant continuous-infusion 5-fluorouracil (5-FU), concurrently with pelvic radiation, followed by postoperative 5-FU-based chemotherapy, remains the standard multimodality approach.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19036689.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 59
  •  go-up   go-down


80. del Casar JM, Corte MD, Alvarez A, García I, Bongera M, González LO, García-Muñiz JL, Allende MT, Astudillo A, Vizoso FJ: Lymphatic and/or blood vessel invasion in gastric cancer: relationship with clinicopathological parameters, biological factors and prognostic significance. J Cancer Res Clin Oncol; 2008 Feb;134(2):153-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphatic and/or blood vessel invasion in gastric cancer: relationship with clinicopathological parameters, biological factors and prognostic significance.
  • The presence of LBVI correlated significantly with tumor stage, lymph node involvement, surgical resectability, histological type and histological grade, being present in a higher percentage among II-IV tumor stage (P = 0.0001), poorly differentiated (P = 0.01), diffuse type (P = 0.009), R1-R2 (P = 0.002) and lymph node-positive (P = 0.005) tumors.
  • CONCLUSION: LBVI provides additional useful information that could be applied to identify gastric cancer patients at risk for recurrence, who might be candidates for further adjuvant therapies.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):874-9 [15681533.001]
  • [Cites] Ann Surg Oncol. 1999 Apr-May;6(3):286-9 [10340888.001]
  • [Cites] Surg Oncol. 2000 Jul;9(1):5-11 [11525306.001]
  • [Cites] Br J Cancer. 1996 Sep;74(5):766-72 [8795580.001]
  • [Cites] Br J Surg. 1993 Mar;80(3):325-8 [8472141.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4324-7 [10969769.001]
  • [Cites] Gastric Cancer. 1998 Mar;1(2):125-133 [11957056.001]
  • [Cites] Int J Biol Markers. 2000 Jan-Mar;15(1):44-50 [10763140.001]
  • [Cites] Science. 2002 Jun 7;296(5574):1883-6 [11976409.001]
  • [Cites] Br J Cancer. 2005 Sep 19;93(6):688-93 [16136051.001]
  • [Cites] Breast Cancer Res Treat. 1991 Jan-Feb;17(3):211-9 [1645606.001]
  • [Cites] Int J Biol Markers. 2003 Jul-Sep;18(3):200-6 [14535591.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):306-12 [15273556.001]
  • [Cites] Int Surg. 1999 Oct-Dec;84(4):331-6 [10667813.001]
  • [Cites] Int Surg. 2000 Oct-Dec;85(4):286-90 [11589593.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Br J Surg. 1993 Aug;80(8):1015-8 [8402053.001]
  • [Cites] Lab Invest. 2003 Sep;83(9):1343-52 [13679442.001]
  • [Cites] Oncology. 2005;69 Suppl 3:4-10 [16301830.001]
  • [Cites] Int J Biol Markers. 2001 Jan-Mar;16(1):37-44 [11288953.001]
  • [Cites] Ann Surg. 2006 Jan;243(1):64-73 [16371738.001]
  • [Cites] Br J Cancer. 2007 Jun 4;96(11):1723-8 [17486129.001]
  • [Cites] Cancer. 1994 Feb 1;73(3):550-5 [8299076.001]
  • [Cites] Int J Biol Markers. 2004 Oct-Dec;19(4):268-74 [15646832.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):234-41 [12679307.001]
  • [Cites] Eur J Surg Oncol. 2004 Apr;30(3):318-24 [15028316.001]
  • [Cites] Surg Today. 2003;33(2):95-100 [12616368.001]
  • [Cites] Cancer Treat Res. 1996;82:235-53 [8849954.001]
  • [Cites] Nat Med. 2000 Apr;6(4):389-95 [10742145.001]
  • [Cites] Int J Cancer. 1991 Sep 9;49(2):203-7 [1879965.001]
  • [Cites] Surgery. 2003 Oct;134(4):720-7; discussion 727-9 [14605635.001]
  • [Cites] J Surg Oncol. 2004 Apr 1;86(1):16-21 [15048675.001]
  • [Cites] Jpn J Surg. 1990 Sep;20(5):545-52 [2243447.001]
  • [Cites] J Chir (Paris). 1998 Oct;135(4):148-54 [9827393.001]
  • [Cites] World J Gastroenterol. 2002 Dec;8(6):994-8 [12439912.001]
  • [Cites] CA Cancer J Clin. 1993 Jan-Feb;43(1):7-26 [8422609.001]
  • [Cites] Surgery. 1995 Apr;117(4):380-5 [7716718.001]
  • [Cites] Surgery. 1990 Feb;107(2):140-8 [1689080.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] Ann Surg Oncol. 2002 Jul;9(6):562-7 [12095972.001]
  • [Cites] Ann Surg. 2003 Jun;237(6):828-35; discussion 835-7 [12796579.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Biochem J. 1969 Jun;113(2):299-305 [4185494.001]
  • [Cites] Anticancer Res. 2001 Jul-Aug;21(4A):2351-5 [11724292.001]
  • [Cites] Ann Surg Oncol. 1995 Jul;2(4):308-13 [7552619.001]
  • [Cites] Eur Surg Res. 1997;29(1):35-41 [9013104.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):795-803 [12360282.001]
  • (PMID = 17628829.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 3.4.21.68 / Tissue Plasminogen Activator
  •  go-up   go-down


81. Widder J, Kastenberger R, Fercher E, Schmid R, Langendijk JA, Dobrowsky W, Pötter R: Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients. Radiother Oncol; 2008 Jun;87(3):367-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients.
  • BACKGROUND AND PURPOSE: To retrospectively analyse a large consecutive cohort of patients with anal cancer for treatment-related factors influencing local control and survival.
  • MATERIALS AND METHODS: All patients referred for primary radiotherapy at Medical University of Vienna in 1990-2002 with anal canal carcinoma without distant metastases were analysed.
  • RESULTS: Median age was 67 years (n=129), the UICC stage distribution was 15%, 58%, and 27% for stages I, II, and III, respectively.
  • Stage and age were significant factors for overall and colostomy-free-survival, N-stage for disease-free-survival.
  • Shorter overall treatment time favoured local control in stage T1-2 (p=.015), higher total radiation dose and female gender were associated with improved local control in T3-4 tumours (p=.021).
  • CONCLUSIONS: These results support potential improvement of anal cancer treatment by studying advanced technology such as IMRT, making it possible to tailor high-dose regions.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501453.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


82. Brosens RP, Belt EJ, Haan JC, Buffart TE, Carvalho B, Grabsch H, Quirke P, Cuesta MA, Engel AF, Ylstra B, Meijer GA: Deletion of chromosome 4q predicts outcome in stage II colon cancer patients. Anal Cell Pathol (Amst); 2010;33(2):95-104
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deletion of chromosome 4q predicts outcome in stage II colon cancer patients.
  • BACKGROUND: Around 30% of all stage II colon cancer patients will relapse and die of their disease.
  • At present no objective parameters to identify high-risk stage II colon cancer patients, who will benefit from adjuvant chemotherapy, have been established.
  • With traditional histopathological features definition of high-risk stage II colon cancer patients is inaccurate.
  • The aim of the present study was to identify chromosomal aberrations that can predict relapse of tumor in patients with stage II colon cancer.
  • MATERIALS AND METHODS: DNA was isolated from 40 formaldehyde fixed paraffin embedded stage II colon cancer samples with extensive clinicopathological data.
  • To analyze differences between stage II colon cancer patients with and without relapse of tumor a Wilcoxon rank-sum test was implemented with multiple testing correction.
  • RESULTS: Stage II<